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 Microtubules are cellular cytoskeletal components that play an integral part in many cell 
functions. Compounds that bind to microtubules and alter their dynamics are highly sought as a 
result of the clinical success of paclitaxel and docetaxel. A series of analogues of the microtubule 
stabilizing dictyostatin were examined to probe biological and biochemical structure-activity 
relationships.  The results were consistent with previous reports showing that 16-
normethyldictyostatin and 15Z,16-normethyldictyostatin lose potency in pacitaxel-resistant cell 
lines that have a Phe270-to-Val  mutation in the taxoid binding site of ?-tubulin.  6-epi-
Dictyostatin and 7-epi-dictyostatin were potent analogues of dictyostatin, and 6-epi-dictyostatin 
was chosen for milligram scale for pre-clinical studies.   
The thalidomide analogue 5HPP-33 was identified as an easily synthesized small 
microtubule perturbing agent, and experiments with isolated tubulin were performed to 
determine its mechanism of action. Tubulin polymerization was used to determine the effect of 
5HPP-33 on normal microtubule formation. In experiments utilizing microtubule associated 
proteins (MAPs) to induce polymer formation, 5HPP-33 inhibited tubulin polymerization, but 
under a different set of conditions appeared to form and stabilize microtubules. The polymer was 
imaged using electron microscopy, which showed that 5HPP-33 caused the formation of spirals 
and rings.  Due to 5HPP-33 failing to compete with known radiolabeled microtubule perturbing 
agents for their respective binding sites, a tritiated version of 5HPP-33 was synthesized. The 
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binding experiments performed showed that [3H]5HPP-33 had a slight affinity for isolated 
MAPs, and this was the reason for the discrepancy between the tubulin polymerization 
experiments.  A binding site for 5HPP-33 could not be determined, making it a possible novel 
microtubule perturbing agent.   
(–)-Pironetin is a microtubule inhibitor that appears to form a covalent linkage to the 
tubulin heterodimer. Although immunoflourescent images showed (–)-pironetin to work in the 
same manner as vinblastine, cellular and biochemical experiments proved that (–)-pironetin is 
mechanistically different from vinblastine.  
The tubulysins are known microtubule destabilizers and bind to the vinca domain on ?-
tubulin. Three analogues of the tubulysins were synthesized and their effects on cell growth and 
microtubule perturbation experiments were determined. WZY-111-63C (N14-
desacetoxytubulysin H) was found to be 50 times more cytotoxic than paclitaxel and vincristine.  
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 1 
1.0  INTRODUCTION 
Microtubules play a role in many cellular processes.  They provide a means of transportation 
from the cell periphery to the nucleus, give structural support to the cell as a part of the 
cytoskeleton, and are the major component of flagella and cilia.  Microtubules also play a crucial 
role in mitosis, serving in the separation of sister chromatids during anaphase and in preparation 
for the division of the parent cell into two daughter cells.  Microtubules are not static structures, 
rather they interconvert between rapid stages of depolymerization and polymerization.  This 
process is known as dynamic instability.  Regulation of dynamic instability is controlled by a 
number of factors in vivo.  Agents that can interfere with the normal function of microtubules 
and arrest cell division are of great importance in cancer treatment. 
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1.1 MICROTUBULE STRUCTURE, FUNCTION AND REGULATION 
1.1.1 Microtubule structure and function 
Microtubules are noncovalent polymers formed from the heterdimers of the protein tubulin.1 
The heterodimeric protein is composed of ? and ? isoforms of similar amino acid sequence, and 
each isoform has a molecular mass of  ~50 kDa.2   The microtubule is a tube composed of 
longitudinal strands of heterodimers called protofilaments.  These protofilaments, typically 14 of 
which, interact laterally to form the microtubule, in which the heterodimers are arranged in a 
left-handed, three-start helix.  The interior of the microtubule is known as the lumen.  Panel A in 
Figure 1 shows the tubulin heterodimer, and Panel B provides a diagram of microtubule 
formation.  Microtubules are arranged in a B-type lattice, where lateral interactions occur 
between adjacent ? monomers and adjacent ? monomers.3  These interactions are uniform 
throughout the helix, except at the seam where the path switches from ? to ? interactions or vice 
versa.  
 
 
 
 
 
 
Panel A shows the quaternary strucuture of the tubulin heteromdimer containing ? and ? subunits.  The monomers 
share a 50% homology at the amino acid level [adapted from Nogales, E et al., Nature, 1998(391):  1994].  Panel B 
shows the formation of protofilaments from head-to-tail interactions of heterodimers.  Heterodimers then associate 
to form the microtubule B lattice. The lateral interactions within the B lattice are between homologous monomers, 
but there is an exception at the seam of the microtubule [adapted from Desai A and Mitchison T, Annu. Rev. Cell 
Dev. Biol., 1997(13):  83-1171]. 
Figure 1.  The tubulin heterodimer and diagram of microtubule formation 
A B 
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Both ? and ? tubulin contain a binding site for the nucleotide guanosine triphosphate 
(GTP).6  The GTP at this site is hydrolyzed after incorporation of the dimer into the microtubule, 
and remains bound to ? tubulin as guanosine diphosphate (GDP).  Microtubules have a distinct 
polarity because of the formation of a layer of newly added GTP containing heterodimers.5  As 
the microtubule lengthens, the GTP is hydrolyzed in these heterodimers leaving heterodimers 
containing GDP in their exchangeable site.  The end from which heterodimers contain GDP and 
readily dissociate from is known as the (–)-negative end, and the end where addition of 
heterodimers occurs containing a layer of GTP containing heterodimers is known as the (+)-
positive end.  The subunits containing GDP are released from the (–) end. The released 
heterodimeric subunits can then actively exchange the bound GDP for GTP, and these subunits 
can be used in another cycle of microtubule polymerization.  The binding site for GTP on ? 
tubulin differs in function from that of the ? tubulin monomer.   It is known as the non-
exchangeable site or N-site due to the lack of exchange for GDP to GTP during microtubule 
depolymerization and the fact that GTP bound at this site is not hydrolyzed during 
polymerization.7 
The process of microtubule formation occurs in three phases termed nucleation, 
elongation and steady-state.8  Nucleation is the slow formation of a small microtubule nucleus 
from soluble tubulin.  After formation of this nucleus, elongation of the microtubule rapidly 
occurs.  Elongation is the rapid addition of heterodimers to the (+) end of the microtubule. After 
a period of elongation, the microtubule reaches a steady state.  The steady state occurs when the 
lengthening and shortening of the microtubule occur at equal rates.   
 4 
Microtubule polymerization and depolymerization does not usually occur in a continuous 
manner with equivalent addition and subtraction of subunits at each end.9, 10 This phenomenon, 
called treadmilling, does occur, but more often the microtubule never reaches an equilibrium 
length.  Experiments have shown that while a given population of microtubules may have an 
average length, a single MT rapidly interconverts between depolymerization and 
polymerization.11  This rapid change is called dynamic instability and allows for microtubule 
function within the cell. 
Dynamic instability is characterized in vitro by four parameters.12 These parameters are 
the rate of microtubule growth, the rate of microtubule shortening, the frequency of catastrophes 
and the frequency of rescues.  Catastrophe is the transition of the microtubules from a 
polymerization state to that of depolymerization and rescue is exactly the opposite process.   
GTP hydrolysis powers dynamic instability with the free energy provided by the release 
of phosphate.   The primary role of GTP hydrolysis is destabilization of the microtubule lattice 
by the formation of weaker lateral interactions within the GDP bound ?-tubulin subunits. 
 
 
 
 
 
  
 
 
 
Figure 2.  Diagram of microtubule dynamics and the role of GTP [adapted from 
Desai and Mitchison, Annu. Rev. Cell Dev. Biol., 1997(13):  83-1171]. 
 5 
GTP-induced polymerization causes instability.  The plus ends of the microtubule contain 
a small layer of GTP-containing subunits that help to stabilize the microtubule and drive 
polymerization.11  The loss of this cap permits rapid depolymerization due to the instability of the 
GDP-bound tubulin.   
1.1.2 Role of microtubules in mitosis 
Mitosis is the process by which the nucleus of the cell divides and produces two genetically 
identical daughter cells from a parent cell.13  Division of the cytoplasm follows mitosis in a 
process known as cytokinesis.  Mitosis is divided into five stages that occur sequentially, 
prophase, prometaphase, metaphase and anaphase, with cytokinesis occurring after the last stage.   
Microtubules are the main functional component of the mitotic spindle.14  The bipolar 
mitotic spindle is made up of the centrosome, which consists of a pair of centrioles, the 
centrosome matrix and an aster.  The attachment of the (–) ends of microtubules to the centrioles 
produces an array of radiating microtubules known as an aster.15  The centrosome matrix consists 
of a number of proteins, which help in the nucleation of the microtubules.   
Microtubule dynamics plays a very important role in all stages of mitosis.  Figure 3 
represents the three phases of mitosis, namely metaphase, anaphase and telophase, in which 
microtubules are known to play a prominent role.   
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During metaphase, the microtubules attach to the kinetochores of the sister chromatid pairs, 
allowing for their correct orientation along the metaphase plate.16  The cell then enters anaphase 
where the microtubules function in separating the sister chromatid pairs by, in concert with 
motor proteins, pulling them to opposite poles of the cell.  A membrane forms around the 
separated chromatin in telophase and prepares for the division of cytoplasm during cytokinesis.17 
1.1.3 Regulation of microtubule dynamics 
The rates of polymerization and catastrophes in vivo are both greater than that observed in vitro 
using purified tubulin.18  This is probably due to the in vivo regulation of microtubules through 
signal transduction pathways, post-translational modifications and binding of regulatory proteins 
to the microtubule lattice. Cells can alter the expression of proteins that destabilize or stabilize 
microtubules. Certain proteins that interact with the microtubules are inactive when 
phosphorylated, and the cell can alter the phosphorylation levels of these proteins.  
Metaphase 
Anaphase 
Telophase 
Figure 3.  Immunoflourescence images displaying the function of microtubules in three phases of 
mitosis [adapted from http:// mitichison.med.harvard.edu/research/microtubules/html]. 
The stages of mitosis were visualized using Hoechst to stain chromatin (blue) and a fluorescently 
labeled secondary antibody to stain microtubules (green). 
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The most well known microtubule-stabilizing factors in vivo are the microtubule-
associated proteins (MAPs).  MAPs bind to the microtubule and stabilize the lattice by cross-
linkage of heterodimers.19  The crosslinkage functions to stifle heterodimer dissociation, 
decrease catastrophes and increase rescue.20  There are four types of well-characterized MAPs:  
MAP1, MAP2, tau in neurons, and MAP4 in non-neuronal cells.  MAP binding in neurons to 
microtubules is in a ratio or 1:4-10, and binding is primarily through electrostatic interactions 
with the acidic C-terminal of the microtubule proteins.  MAP binding is negatively regulated by 
phosphorylation, and over-phosphorylation of tau plays a role in the pathogenesis of Alzheimer’s 
disease.1 
Proteins that increase the rate of catastrophes and decrease rescues include kinesins, 
stathmin, and microtubule severing proteins.21-23 Kinesins are motor proteins that move by 
walking from the (–) to (+) ends of microtubules.  It has been shown in Xenopus eggs that 
immunodepletion of  kinesin, XKCM1, causes an increase in microtubule length and a decrease 
in catastrophe frequency.24   
Stathmin/Op18 is a small protein that binds in a ratio of 1:2 to tubulin heterodimers as 
determined by electron microscopy.25  Stathmin not only increases the catastrophe frequency but 
also lowers the amount of soluble tubulin available.  X-ray crystallography studies with the 
stathmin like domain (SLD) of RB3, a neuron-specific homologue of the stathmin family of 
proteins, show that binding of the protein to tubulin changes the conformation of the 
protofilament.26  As presented in Figure 4, binding of SLD-RB3 to tubulin causes the 
heterodimer to curve.   
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A.) The stathmin like binding domain of RB3 bound to two heterodimers.  B.) The (?) represents the GTP 
exchangeable site on ? tubulin and (?) represents the nonexchangeable site on ? tubulin.  The intermediate domain 
(I) is rotated toward the nucleotide binding domain in the straight protofilament to allow for lateral interactions to 
occur [adapted from Ravelli R, Nature, 2004(428):  198-20226]. 
 
 
The binding of SLD-RB3 is associated with movement in the H6-H7 loops and the intermediate 
domain in the both the ? and ? subunits.  This movement causes a loss of favorable lateral and 
longitudinal interactions within and between the protofilaments.   
 The microtubule severing proteins seem to play multiple roles within the cell.  Katanin, a 
microtubule severing protein in the ciliate protozoa Tetrahymena, promotes microtubule 
assembly in ciliary microtubules, but decreases polymer mass of internal microtubules.27  Post-
translational modifications to tubulin seem to be markers for the severing of the microtubules. 
 
Figure 4.  Conformational changes to the tubulin heterodimer associated with SLD-RB3 binding. 
A B 
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1.2 MICROTUBULE PERTURBING AGENTS 
The importance of microtubules to mitosis and the potential to interfere with delicate dynamics 
of microtubules has lead to the search and development of many microtubule interacting 
compounds.  Microtubule perturbing agents can be roughly classified into two broad groups 
based upon the mechanism by which they disrupt normal microtubule function. These include 
agents that stabilize microtubule formation and agents that destabilize or inhibit polymer 
formation.28  These agents can further be classified by the location of their binding site to tubulin 
and/or the microtubule. 
1.2.1 Paclitaxel and other known microtubule stabilizers 
Paclitaxel was originally isolated from the bark of the yew tree Taxus brevifolia.29  Its ability to 
stabilize microtubules and increase the polymer mass was recognized in 1979 by Schiff and 
Horwitz.30  Paclitaxel was clinically approved in 1995 and has been shown effective for the 
treatment of breast, ovarian and non-small cell lung carcinomas.28  The binding of paclitaxel to 
the microtubule stabilizes the lateral interactions between heterodimers.  Paclitaxel binds to the 
?-tubulin subunit and preferentially binds to polymerized tubulin.  Interestingly, high resolution 
cryoelectron microscopy studies of zinc cation- and paclitaxel-stabilized sheets of tubulin and 
computational models of microtubules from these sheets strongly suggest that the taxane binding 
site (i.e., where paclitaxel binds) is in the lumen of the microtubule. Studies with cyclostreptin, a 
microtubule stabilizer that binds covalently to the taxoid site, have shown that taxane site 
binding may be a two-step mechanism.31  Taxane site agents may first bind to an external site on 
the microtubule surface, and then transfer to an interior site within the lumen.  
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 The great clinical success of paclitaxel has led the search for other microtubule 
stabilizing agents.  Microtubule stabilizers have been identified from a number of sources, such 
as marine corrals and sponges, soil bacteria and plants.  The epothilones, discodermolide, 
laulimalide, dictyostatin, and peluroside A have been identified to possess the same general 
mechanism of action as paclitaxel.32-36  The structures of some of these compounds are presented 
in Figure 5.  This suggests that, and has been proven in competitive binding assays, these drugs 
bind to the same or only slightly different site on the ?-tubulin subunit of the microtubule 
polymer.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.  Paclitaxel and other microtubule stabilizers isolated from natural sources. 
O
N
H
O
OH
O
O
O
HO
O O
OH
H
O
H
O
O
O
Paclitaxel
OH
NH2
O
HO
OH
O
O
O
OH
Epothilone
A: R = H
B: R = CH3
O
S
N
O
R
OH
OOHO
Discodermolide
O
O O
O
OH
H OH
O
Laulimalide
 11 
Laulimalide and peloruside A are the only compounds that bind to a completely different binding 
site, but this site has yet to be identified.36, 37 
1.2.2 Microtubule destabilizers:  Vinca domain binding agents and colchicine site 
Colchicine was the first compound identified possessing tubulin-related antimitotic activity.  
Radiolabeled colchicine provided the first identification and purification of tubulin from the 
bovine brain – in fact, tubulin was initially called colchicines-binding protein.38  Colchicine 
binds to the ?-subunit of tubulin and the kinetics of binding occurs in two phases.  The initial 
phase of colchicine binding to tubulin is relatively fast, but upon further binding it produces a 
slow conformation change within the protein.  Colchicine binds tightly to tubulin and 
dissociation occurs very slowly.  When a colchicine-tubulin complex is incorporated into a 
microtubule polymer the dynamics of the microtubule are suppressed, and at high colchicine 
concentrations assembly is completely inhibited.   
 
 
 
 
 
 
 
Podophyllotoxin and curacin A have been reported to competitively inhibit the binding of 
colchicine to tubulin, and possess similar antimitotic capablilities.39, 40   Some examples of 
colchicine site binding agents are shown in Figure 6. 
Figure 6.  Examples of colchicine site binding agents. 
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The vinca alkaloids, vincristine and vinblastine, were first isolated from the leaves of the 
periwinkle plant Catharanthus roseus.28  Since the 1950s, the vinca alkaloids have been in 
clinical use for childhood leukemia and adult hematological malignancies.  They are 
characterized as microtubule assembly inhibitors; however, turbidimetric analyses have revealed 
that these agents cause an aberrant tubulin polymerization reaction.41, 42  Electron microscopy 
studies show the aberrant tubulin polymer to be in the form of spirals and rings.   
 The binding site of vinca alkaloids is located on the ?-subunit of the tubulin dimer near 
the exchangeable nucleotide site and is termed the vinca binding domain.43  The term "domain" 
is used instead of "site" due to the discovery of compounds that inhibit vinca alkaloid binding to 
this part of ?-tubulin in a noncompetitive manner. All compounds that bind to this domain share 
the common characteristics of inhibiting microtubule assembly and preventing GTP hydrolysis.  
 The competitive inhibitors of the vinca domain are vinca alkaloids, maytansine and 
rhizoxin.44  The noncompetitive inhibitors of binding are the peptides/depsipeptides such as 
dolastatin 10, phomphosin A, cryptophycin, hemiasterlin, and diazonamide A.45  It is believed 
that the noncompetitive inhibitors interfere with vinca alkaloid binding by sterically hindering 
the binding site.  This leads to the assumption that the vinca alkaloid binding site overlaps with 
the binding site of the noncompetitive inhibitors.  Some examples of vinca domain binding 
agents are presented in Figure 7. 
 
 
 
 
 
Figure 7.  Examples of compounds that bind to the vinca domain on tubulin. 
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Further evidence for overlapping binding sites is given by the fact that all of the noncompetitive 
and competitive inhibitors prevent GTP nucleotide exchange on ?-tubulin.  Vinca alkaloids only 
weakly block nucleotide exchange.43 
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1.3 MECHANISMS OF RESISTANCE IN ANTIMICROTUBULE 
CHEMOTHERAPY 
Resistance is a major problem associated with most chemotherapy.46 There are many 
mechanisms by which the cell combats antimicrotubule therapy.  The most common mechanisms 
are the over expression of the P-glycoprotein pump, overexpression of certain isotypes of 
tubulin, and mutations which affect the binding of microtubule perturbing agents to their target 
site.  The importance of each of these mechanisms has been determined clinically, and 
compounds that can overcome this resistance are heavily sought after.   
The most common cause of resistance in antimicrotubule therapy is believed to be the 
over expression of the P-glycoprotein pump in cancer cells, which increases toxin and drug 
efflux in humans.46 The MDR1 (more accurately, ABCB1) gene encodes for the P-glycoprotein 
pump.  P-glycoprotein is a membrane bound protein that is part of the adenosine triphosphate 
binding cassette transporter.47  The taxanes, both paclitaxel and docetaxel, colchicine, and the 
vinca alkaloids are well-characterized substrates for this pump.48, 49  The binding of adenosine 
triphosphate and hydrolysis of a phosphate group powers the active pumping of drugs out of the 
cell.  Figure 8 shows how the hydrolysis of ATP is used to actively pump drugs out of cancer 
cells.   
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There are six different isotypes of ?-tubulin that can be found in cells.50  These isotypes are 
differentiated into six different classes I, II, III, IVa, IVb, and VI.  Class I ?-tubulin is the most 
common type, but recent results indicate that certain isotypes are overexpressed in cancer cells.50 
 It is believed that class III ?-tubulin incorporation destabilizes microtubules and this overcomes 
treatment with the microtubule stabilizing agents.  A study utilizing 39 patients with recurrent 
breast cancer notes a high level of correlation between overexpression of class III ?-tubulin and 
failure to respond to treatment with docetaxel.51   
 Cancer cells grown in the presence of paclitaxel and verapamil, a P-glycoprotein pump 
inhibitor, become resistant to paclitaxel treatment through alterations in the taxane binding site 
on ?-tubulin.52  Cell lines resistant to epothilone A and B treatment by the same mechanism have 
also been isolated.53  Although identification of the mutated amino acids within these cells has 
provided important information regarding the interactions of these compounds within the binding 
site, this method of resistance has not been shown to be clinically relevant.  A recent study by 
Figure 8.  Schematic of the P-glycoprotein pump 
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OUT
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ATP ADP+Pi
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Hasegawa et al. reports that the frequency of mutations to class I ?-tubulin in human breast 
cancer could be as low as 1.6%.54 
 The importance and clinical success of many microtubule perturbing agents in the 
treatment of cancer compels further research into agents that overcome these resistance 
problems.  With the FDA approval of ixabepilone, an epothilone analogue, for the treatment of 
taxane-refractory cancers and the number of microtubule perturbing agents in clinical trial, it is 
clear that the such research is needed to improve chemotherapeutic treatment.28  It was therefore 
hypothesized the the evaluation of potential microtubule perturbing agents for their mechanisms 
and kinetics will lead to new chemotherapeutic agents that could improve current patient 
treatment.   
 Three different projects were undertaken to provide potential chemotherapeutics and to 
provide more information about the mechanisms of already known microtubule perturbing 
agents.  To gain insight into the structure-activity relationship of the potent microtubule stabilizer 
dicytostatin, analogues of the parent compound were synthesized and evaluated for their effects 
on cancer cells and purified tubulin.  Then experiments were performed to determine the 
mechanism by which the small microtubule perturbing agent, 5HPP-33, affected microtubule 
dynamics.  Finally, cell-based and biochemical assays were performed on (–)-pironetin, its 
analogues, and the tubulysins to compare their microtubule inhibiting abilites to already 
previously characterized compounds.  From this work many novel microtubule perturbing agents 
were discovered and common mechanisms of action were revealed.   
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2.0  MATERIALS AND METHODS 
2.1 CHEMISTRY 
2.1.1 General Information 
All reactions were performed in oven-dried glassware under an inert atmosphere of nitrogen 
unless otherwise stated.  Anhydrous THF, CH2Cl2 and benzene were obtained from distillation 
from CaH2.  Melting points for all compounds were performed on a Fisher-Johns melting point 
apparatus.  Infrared spectra were performed on a Perkin Elmer spectrum 100 FT-IR 
spectrometer.  1H-NMR spectra were recorded on a 400 MHz Varian spectrometer.  13C-NMR 
spectra were recorded on a Bruker spectrometer equipped with a cyroprobe at 150 MHz or on a 
Varian spectrometer on a 100 MHz.  Spectra were obtained using CDCl3 as the solvent and 
chemical shifts were reported relative to residual CHCl3 (7.26 ppm) for 
1H spectra and CDCl3 
(77.0 ppm) for 13C spectra.  High resolution mass spectra were obtained an Applied Biosystems 
4700 MALDI-TOF-MS.  Analytical thin layer chromatography was performed on EM Reagent 
0.24 nm silica gel 60-F plates.  Flash chromatography was performed as described previously 
using Aldrich Silica Gel, Merck grade 9385 (230-400 mesh).   Analytical gas chromatography 
was performed on a 5890 Series II gas chromatograph equipped with a Hewlett Packard 5971 
Series mass selective detector.  Purification of the radiolabeled compound was performed using a 
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Nova-Pak C18 column (3.9 x 150 mm) on a Waters 2695 separation module equipped with a 
Waters 2487 dual wavelength absorbance detector.  A Packard FlowScintillation analyzer was 
used to determine the radioactive purity of the compound.  Commercial reagents were purchased 
from Aldrich Chemical Company (Milwaukee, WI).   
 
2.2 EXPERIMENTAL PROCEDURES 
NEt3ICl2
 Benzyltriethylammonium dichloroiodate (4):55 A 250 mL Erlenmeyer flask 
equipped with a stir bar was charged with water (39 mL), hydrochloric acid (2.0 mmol) and 
iodine (2.0 mmol). The mixture was stirred for 45 minutes at room temperature, and then chilled 
to 0 oC in an ice bath.  The mixture was titrated with a solution of 6% NaClO (20 mL) over a 
period of 4 hours.  The endpoint of the reaction was observed when the solution turned yellow.  
An aqueous solution of 10% NaI was added dropwise to the reaction until a slight orange color 
was observed.  The mixture was then slowly poured into a stirring solution of 
benzyltriethylammonium chloride (3.0 mmol) in water.  The precipitate was collected by vacuum 
filtration, and washed with water (100 mL 3x).  The solid was dried in vacuo for 17 hours to 
obtain a fine yellow powder (8.5 g, 69%):  mp 84-88 oC (lit mp 84-86 oC); 1H NMR (400 MHz, 
CDCl3): ? 7.46-7.54, (m, 5H), 4.44, (s, 1H), 3.31, (q, J = 7.2 Hz, 6H), 1.52, (t, J = 7.2 Hz, 9H); 
13C NMR (100 MHz, CDCl3): ? 132.60, 131.50, 130.10, 126.30, 61.59, 53.43, 8.70.   
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H2N
I
 4-Iodo-2,6-diisopropylaniline (5):56  A 250 mL three neck flask equipped with a stir 
bar was charged with 2,6-diisopropylaniline(2) (11 mmol), CH2Cl2 (27 mL), MeOH (27 mL), 
and NaHCO3 (21 mmol).  The mixture was chilled to 0 
oC, evacuated and backfilled with N2 
(3x).  Compound 6 (10.6 mmol) was added to the flask in a solution of CH2Cl2 over a period of 
15 minutes.  The reaction mixture was stirred at 0 oC for 5 minutes, then warmed to room 
temperature.  The reaction stirred for an additional 25 minutes and then was poured into 
NaHCO3 (250 mL).  The organic layer was extracted with CH2Cl2 and washed with NaHCO3 
(2x).  The combined organic layers were washed with H2O (3x), and extracted with CH2Cl2.  The 
organic layers were dried over MgSO4, and concentrated in vacuo.  The crude product was 
purified by flash chromatography (19:1 hexanes-EtOAc) to yield 2.56 g (80%) of the title 
compound as brown oil:  1H NMR (400 MHz CDCl3):  ? 7.28 (s, 2H), 3.74 (br s, 2H), 2.84 
(septet, J = 6.8 Hz, 4H), 1.24 (d, J = 6.8 Hz, 12H). 
 
N
O
O
HO
I
2-(4-Iodo-2,6-diisopropylphenyl)-5-hydroxy-1H-isoindole-1,3-dione(6):  
A 25 mL flask was equipped with a stir bar, condenser, and 4Å  activated molecular sieves.  To 
this flask, 4-hydroxyphthalic acid (2) (0.79 mmol), compound 5 (0.66 mmol) and CH3CO2H (2 
mL) were added. The mixture was heated to 100 oC for 2 h, after which it was cooled to room 
temperature and poured into NaHCO3 (50 mL).  The organic layer was extracted with Et2O and 
washed with water (3x). The organic layer was dried over MgSO4 and solvent was removed in 
vacuo.  The crude product was purified using a small plug of silica gel (3:2 hexanes-EtOAc) to 
yield 0.12 g (42%) of the title compound as a white crystalline solid: mp 55-59 oC; IR:  3365 
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(hydroxy stretch), 2964 (methyl stretch), 2928 (methyl stretch), 1719 (carbonyl), 1604 (amine), 
1467 (aromatic), 1373 (aromatic), 1269 (aromatic), 1097 (aromatic), 854 (aromatic), 755 (ortho 
substitution pattern); 1H NMR (400 MHz, CDCl3):  ? 7.84 (d, J = 8.0 Hz, 1H), 7.56 (s, 1H), 7.36 
(d, J = 2.4 Hz), 7.19 (dd, J = 8, 2.4, 1H), 6.09 (br s, 1H), 2.64 (septet, J = 6.8 Hz, 4H), 1.14 (d, J 
= 6.8, 12H); 13C NMR (150 MHz, (CDCl3): ? 167.67, 167.65, 161.71, 149.77, 134.55, 127.10, 
126.13, 123.67, 121.07, 110.97, 97.11, 96.94, 29.25, 23.83, 23.80; HRMS (MALDI-TOF):  
[M+H]+ calculated for C20H20INO3 m/z 449.0488, found 450.0542 
 
N
O
O
HO
3H
[4-3H]2-(2,6-Diisopropylphenyl)-5-hydroxy-1H-isoindole-1,3-dione (7):57 
A 5 mL round bottom flask equipped with a stir bar was charged with compound 6 (0.6 μmol), 
Et3N (0.6 μmol), 10% Pd/C (0.6 mg) and MeOH (1 mL) under an inert atmosphere. The flask 
was degassed by the application of three freeze-pump-thaw cycles.  The frozen solution was then 
covered with an atmosphere of tritium gas supplied by a Trisorber® (IN/US Systems).  The 
mixture was allowed to warm to room temperature and stirred for 1 h.  The reaction was filtered 
to remove the Pd/C and distilled to remove the radioactive solvent [Note: This is an extremely 
proficient way to make tritiated methanol; those wishing to perform such reactions should 
explore other solvents to find those that are not tritiated by this procedure].  The crude product 
was purified by HPLC and the total yield was determined using a calibration curve generated 
using nonradiolabeled compound.   An analogue of compound 3 was used as an internal 
standard.  Specific activity was determined from the amount of radioactivity determined by 
scintillation spectrometry divided by the amount of material (mmol) present.   
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2.3 BIOLOGY 
2.3.1 Materials 
Bovine brains were obtained from a local slaughterhouse.  N-morpholinoethane sulfonate, 
adenosine 5’-triphosphate (ATP), guanosine 5’-triphosphate (GTP) and 2’,3’-dideoxyguanosine-
5’-triphosphate (ddGTP) were obtained from USB (Cleveland, OH). Coomassie G250 stain, 
tris(hydroxymethyl)aminomethane (Tris), glycine and sodium dodecylsulfate were obtained from 
Bio-Rad Labratories (Hercules, CA).  Glycerol was from Invitrogen (Carlsbad, CA). Sodium 
hydroxide was obtained from Fisher (Pittsburgh, PA).  Uranyl acetate and carbon-coated formvar 
grids were generous gifts from the Center for Biological Imaging at the University of Pittsburgh.   
The Drug Synthesis and Chemistry Branch, National Cancer Institute, provided normoisotopic 
and tritiated paclitaxel (16.2 Ci/mmol) and also normoisotopic and tritiated dolastatin 10 (1.96 
Ci/mmol).  Discodermolide, [3H]discodermolide (specific activity 14.4 Ci/mmol), epothilone B 
and [14C]epothilone B (specific activity 111 mCi/mmol)  were generous gifts from Novartis 
Pharma AG.  Dictyostatin was synthesized as described previously.59  [3H]Vinblastine (specific 
activity 8.50 Ci/mmol was obtained from GE Healthcare Bio-sciences (Picataway, NJ).  The 
syntheses of the analogues tested here are reported elsewhere.59-62 Cell lines (1A9, Ptx10 and 
Ptx22) were a gift from Drs. Tito Fojo and Paraskevi Giannakakou at the NIH.  5HPP-33 was a 
generous gift from Dr. Pui-Kai Li at The Ohio State University.  MAPs were a generous gift 
from Dr. Ernest Hamel at the NIH.  Rabbit anti-phosphohistone H3 antibody was purchased from 
Upstate Cell Signaling (Charlottesville, VA).  Cy3-labeled donkey anti-rabbit and fluorescein 
isothiocyanate (FITC)-labeled anti-mouse secondary antibodies were from Jackson 
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Immunoresearch (West Grove, PA).  All other chemicals including mouse anti-alpha tubulin 
antibody were purchased from Sigma (St. Louis, MO).   
 
2.3.2 Antiproliferative assays 
Antiproliferative assays were performed as described previously.63, 64  Cells were seeded into 96-
well plates, allowed to attach and grow for 48 h. One plate of cells was used for a time zero cell 
number determination (N=16), and cells in other plates were treated for 72 h or 96 h with either 
DMSO (0.5% v/v; N = 8 for each plate) or a range of concentrations, in quadruplicate, of test 
agents. Cell number was determined spectrophotometrically at 490 nm minus absorbance at 630 
nm after exposure to 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium (MTS) and N-methylphenazine methylsulfate. The fifty percent 
growth inhibitory concentrations (GI50) of test agents were calculated from the 
spectrophotometrically determined growth of the control cells over the 72 h period. The 
antiproliferative assays for the 1A9 cells and its mutants, and the NIH3T3 cells and its 
transfectants with multidrug resistant pumps (NIH3T3-MDR-G185 and NIH3T3-MDR-V185), 
were performed as described in the literature.65 
2.3.3 Flow cytometry 
The flow cytometry experiments were performed as described by Li et al.66  Labeling cells with 
propidium iodide and the mitotic specific antibody, TG3, allowed for quantitation of the amount 
of 1A9 cells undergoing mitosis.  1A9 cells were trypsinized and washed.  They were then 
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resuspended in 500 ?l of RPMI and 500 ?l of fetal calf serum and 3 mL of ice-cold 70% ethanol 
was added dropwise. The cells were kept at 4ºC for at least 30 minutes, centrifuged, resuspended 
in blocking solution 2% in bovine serum albumin (BSA) in phosphate buffered saline (PBS), and 
incubated at 4ºC overnight. The cells were then centrifuged, resuspended in blocking solution 
with TG3 antibody (diluted 1:10, hybridoma cell culture medium), and allowed to incubate for 
30 minutes. After washing with blocking solution, the cells were stained with FITC-conjugated 
goat anti-mouse secondary antibody for 30 minutes.  The cells were then centrifuged, 
resuspended in 450 ?l PBS, 450 ?l of propidium iodide solution (50 ?g/ml in PBS), 50 ?l RNase 
solution (5 mg/ml in PBS), and allowed to incubate for 30 minutes.  The suspension was then 
passed through a nylon mesh filter and analyzed on a FACSort flow cytometer (Becton 
Dickinson). Fluorescein-5-isothiocyanate (FITC) fluorescence was monitored with a 525 nm 
bandpass filter and propidium iodide with a 585 bandpass filter. 
2.3.4 Purification of tubulin from bovine brain 
Tubulin was extracted from two freshly-obtained bovine brains using a modified version of 
Hamel’s procedure.67  Previous to the morning of the experiment, two extraction buffers, labeled 
Solution A and Solution B, were prepared.   Solution A was 0.1 M MES, pH 6.4, containing  
1 mM ethyleneglycoltetraacetic acid (EGTA), 4 M glycerol, 1 mM MgCl2, 1 mM  
2-mercaptoethanol, 0.1 mM ethylenediaminetetraacetic acid (EDTA) and 0.1 mM GTP.  
Solution B was the same as Solution A but without 4 M glycerol.   
All centrifugations were performed in a Beckman-Coulter Ti 45 rotor.  Bovine brains 
were homogenized in a blender with 0.75 mL/g of Solution A at 0 oC.  The homogenate was 
clarified by spinning at 6,000 rpm for 15 min at 0 oC.   The homogenate was transferred to 
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Beckman centrifuge tubes and centrifuged at 0 °C at 28,000 rpm for 44 min.  The supernatant 
was collected in a clean autoclaved beaker and ATP and GTP were added to make the final 
concentration in the supernatant 1 mM and 0.3 mM, respectively.  The supernatant was divided 
into six aliquots and incubated at 37 °C for 40 min.  The aliquots were transferred to centrifuge 
tubes and centrifuged at 37 °C at 28,000 rpm for 44 min.  The supernatant was discarded and the 
pellet was resuspended in 10 mL/ brain of Solution B.  The pellet was incubated on ice for 30 
min.  The solution was transferred to centrifuge tubes and centrifuged at 24,000 rpm for 30 min 
at 0 °C. The amount of supernatant was determined. Each 1 mL of the supernatant was treated 
with 0.553 g of glycerol (to give a final concentration of 4 M) and 50 μL of a solution containing 
MES, pH 6.4, with EGTA, MgCl2, 2-mercaptoethanol and EDTA to give concentrations of these 
components as per solution Solution A were added.  ATP and GTP were added to give final 
concentrations of 1 mM and 0.3 mM, respectively.  The mixture was incubated at 37 oC for 1 h 
and centrifuged at 37 oC at 28,000 rpm for 44 min.     The supernatant was discarded and the 
pellet was homogenized in 6.25 mL/brain of Solution B.  The rehomogenized pellet was 
incubated on ice for 30 min and centrifuged at 24,000 rpm for 30 min.  The concentration of 
protein was determined using the Bradford method, and adjusted (if needed) to a concentration 
of 27.5 mg/mL with Solution B.68 The High-MES pellet was formed using 0.5 mg/mL 2 M 
lyophilized MES at pH 6.9 for a final concentration of 1.6 M.  GTP and dithiothreitol (DTT) 
(final concentrations of 1 mM and 2 mM, respectively) were then added and the mixture was 
incubated for 45 min at 37 oC.  The mixture was transferred to centrifuge tubes and centrifuged 
for 44 min at 28,000 rpm.  The pellet was homogenized in 8-10 mL of cold 1 M MSG, pH 6.6.  
The rehomogenized pellet was incubated for 2 h on ice and centrifuged at 24,000 rpm at 0°C for 
30 min.  The next cycle of polymerization was induced by the addition of 1 mM GTP to the 
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supernatant and incubation for 1 h at 37 oC.   The mixture was centrifuged at 40,000 rpm at 37 oC 
for 40 min, and then the pellet was homogenized in 8-10 mL of 1 M MSG and incubated on ice 
for 1 h.  A final centrifugation was performed at 0 oC at 40,000 rpm for 40 min.  The 
electrophoretic homogeneity of the protein was determined by SDS-PAGE gel electrophoresis, 
and protein concentration was determined by the method of Lowry.69  
2.3.5 High-content analysis of mitotic arrest 
Detailed conditions for the high-content analysis of microtubule perturbing agents using a cell 
based immunoflourescence assay have been described previously.70  Briefly, HeLa cells were 
plated at a cell density of 8000 cells per well in coolagen-1 coated 384-well microplates.  Cells 
were allowed to attach and spread for 3-8 h and treated with either vehicle dimethyl sulfoxide 
(DMSO) or ten two-fold concentrations gradients of test agents and incubated for an additional 
20 h at 37 oC.  After the incubation, cells were fixed with formaldehyde containing 10 μg/mL 
Hoechst 33342 to stain nuclei/chromatin, permeabilized with Triton X-100 and simultaneously 
immunostained with antibodies against ?-tubulin (mouse monoclonal, 1:2500 dilution) and 
phosphohistone H3 (rabbit polyclonal, 1:1000 dilution) followed by  FITC–labeled donkey anti-
mouse IgG (1:250). Each well was imaged on an ArrayScanII  (Cellomics Inc.) using an Omega 
XF93 filter set at excitation/emission wavelengths of 350/461 nm (Hoechst), 494/519 nm (FITC) 
and 556/573 nm (Cy3).  Images were analyzed with the Target Activation Bioapplication 
(Cellomics, Inc.).  The algorithm provided quantitative measurements of nuclear FITC and Cy3 
intensity, cell density, and of mean and total nuclear Hoechst 33342 intensities.  Microtubule 
mass was defined as the average FITC intensity in an area defined by the Hoechst-stained nuclei.  
To estimate the percentage of cells with elevated phosphohistone H3 levels and with condensed 
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chromatin, thresholds were defined as the average intensity plus one standard deviation of 
Hoechst or Cy3 intensities in anti-phosphohistone H3- or Hoechst 33342-stained cells, 
respectively, using a minimum of 1000 vehicle-treated cells per well.  Cells were classified as 
positive if their average intensities in the Hoechst or Cy3 channel exceeded these thresholds.  
The EC50 was the effective concentration of drug that decreased cell growth by 50% compared to 
vehicle treated with control. 
2.3.6 Tubulin assembly in vitro 
Assessing the ability of agents to inhibit tubulin polymerization in monosodium glutamate 
The ability of agents to inhibit tubulin assembly was assessed in a standard assay utilizing 
MSG.71 Electrophoretically homogeneous bovine brain tubulin (final concentration 10 ?M; 1 
mg/mL) was preincubated with test agents dissolved in DMSO (4% v/v final concentration) and 
monosodium glutamate (0.8 M final concentration, pH 6.6) for 15 min at 30 oC.  The reaction 
mixture was cooled to 0 oC and GTP (0.4 mM final concentration) was added.  Reaction 
mixtures were transferred to cuvettes held at 2.5 oC in a Beckmann 7400 multichannel 
spectrophotometer reading absorbance (turbidity) at 350 nm in each cuvette every 15 sec.  
Baselines were established and temperature was quickly raised to 30 oC (in approximately 1 
min). After 20 min, the temperature was returned to 2.5 oC.  The change in absorbance 20 min 
after samples reached 30 oC was used to calculate extent of polymerization.  The change in 
absorbance at this time point for vehicle plus no GTP was considered 100% assembly inhibition 
(negative control), while the change in absorbance for GTP plus vehicle was taken as 0 % 
inhibition (positive control).  
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Percent inhibition was calculated by:   
((absorbance of positive control at 20 min – absorbance of compound at 20 min)/absorbance of 
positive control at 20 min) * 100 
A linear curve of concentration versus percent inhibition was used to extrapolate a value for the 
IC50, the concentration at which 50 % of tubulin assembly was inhibited.   
 
Assessing the effects of agents on induction of tubulin assembly in monosodium glutamate 
Tubulin assembly was monitored by turbidity development at 350 nm as described previously.72  
Reaction mixtures (0.25 mL final volume) contained tubulin  (1 mg/mL; 10 μM), MSG (0.8 M 
from a stock solution adjusted to pH 6.6 with HCl), DMSO (final volume 4% v/v), and test agent 
(10 μM). If GTP was added, it was at concentration of 0.1 or 0.4 mM.  Reaction mixtures 
without test agent were cooled to 0 °C and added to quartz cuvettes held at 0.25–0.5 °C a 
temperature-controlled (via a Peltier unit), 6-sample Beckman DU 7400 spectrophotometer 
(Beckman Coulter). Test agent in DMSO was then rapidly mixed into the reaction mixture. 
Absorbance at 350 nm was monitored in each cuvette every 15 sec. Each 6-sample run contained 
one positive control (paclitaxel, 10 μM final concentration) and one negative control (DMSO 
only). Baselines were established at 0.25–2.5 °C and temperature was rapidly raised to 30 °C (in 
approximately 1 min) and held there for 20 min. The temperature was then rapidly lowered back 
to 0.25–2.5 °C. The change in absorbance 20 min after samples reached 30 °C was used to 
calculate the extent of polymerization.  
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Tubulin polymerization in the complete system 
The effect of 5HPP-33 on tubulin polymerization was determined using microtubule associated 
proteins (MAPs) to induce assembly.  Assembly was monitored at 350 nm on a 250 Gilford 
spectrophotometer equipped with a Peltier temperature controller and a mechanical multicuvette 
system as described previously.63  Reaction mixtures contained 1.0 mg/mL tubulin purified from 
bovine brain, 0.75 mg/mL MAPs, 400 μM GTP, 0.1 M MES pH 6.9, various concentrations of 
test agent, and 4% DMSO.  If Mg2+ was included in the assay, it was via addition of 0.5 mM 
MgCl2 to determine the effects of Mg
2+ on the activity of 5HPP-33.  Reaction mixtures without 
test agent were cooled to 0 oC and added to precooled cuvettes at the same temperature.  The 
four-sample run contained various concentrations of 5HPP-33 in DMSO and 4% DMSO without 
test agent as a positive control.  Samples were held at 0 oC for 5 min to establish a baseline and 
then the temperature was the rapidly raised to 30 oC for 30 min.  To assess 5HPP-33 full effects 
on microtubule polymerization the temperature was again decreased to 0 oC and held for 15 min.  
The IC50 for 5HPP-33 was determined using the change in absorbance of vehicle at 30 
oC as 
100% assembly and comparing that to baseline (0% assembly).   
2.3.7 Radioligand displacement studies 
Saturation Binding Experiments with [
14
C]Epothilone B  
Determination of the equilibrium binding constant (Kd) for epothilone B was determined as 
described previously.63, 72   An 80 μM stock solution of [14C]epothilone B was prepared in 50% 
DMSO.  Samples of [14C]epothilone B at 0.005-2 μM were prepared in 4:1 (v/v) 0.75 M 
MSG/DMSO (total volume 50 μL) and warmed to 37 °C.  Microtubules were preformed in 
separate tubes by incubating 2.5 μM tubulin and 25 μM ddGTP in 0.75 M for 30 min at 37 °C.  
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Equal volumes (50 μL each) of the radiolabeled compound mixtures and microtubule solutions 
were mixed and incubated for 30 min at 37 °C.  Reaction mixtures were then centrifuged in a 
Beckman Allegra TM 64R at 14,000 rpm for 30 min at room temperature. The amount of 
radiolabel in the supernatant was determined by scintillation spectrometry in a LS6500 Beckman 
multi-propose scintillation counter.  Non-specific radiolabel binding was determined from 
competition experiments with 8 μM discodermolide and processing as described above.  
Saturation binding data for [14C]epothilone B and was analyzed using a modified version of 
Swillens’ equation that accounts for ligand depletion:73,74 
 
Total Binding = {((Bmax x ([L]T – [L]B))/(KD + (([L]T – [L]B))} + ([L]T – [L]B) x
 NS 
Bmax = Number of binding sites 
[L]T = Amount of radioligand added 
[L]B = Amount of ligand bound to tubulin polymer  
NS = Fraction of radioligand bound to nonspecific sites   
 
Non-linear regression analysis was performed using GraphPad Prism software that allows for the 
simultaneous fitting of nonspecific and total binding data.   
 
Determination of Ki values for dictyostatin analogues utilizing [
14
C]Epothilone B 
Inhibitors in 4:1 (v/v) 0.75 M MSG/DMSO were pre-incubated with radiolabeled compound in a 
final volume of 50 μL for 10 min at 37 °C.  To this mixture, 50 μL of microtubules that were 
formed as described above were added and the resulting mixture was incubated for 30 min at 37 
°C.  Reaction mixtures were centrifuged as described above, and a 50 μL aliquot of supernatant 
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was analyzed by scintillation spectrometry.  The equilibrium inhibition constant (Ki) values for 
dictyostatin and its analogues were determined using a modified Hanes analysis:75 
 
[S]/? = Kd x (1 + [I]/Ki) + [S] 
[S] = Free concentration of [14C]epothilone B  
? = Fractional saturation of microtubule sites by epothilone B and inhibitor.   
 
GraphPad Prism was used for linear regression, providing the –Kd value as the x-intercept in the 
absence of inhibitor.  The x-intercept in the presence of inhibitor, –Kd(1+[I]/Ki), was used to 
calculate the Ki values. 
 
Saturation Binding Experiments with [
3
H]Discodermolide 
Determination of the Kd for discodermolide was determined as described above for epothilone B.  
A stock solution of 50 μM [3H]discodermolide was prepared in 50% DMSO.   Samples of  
[3H]discodermolide at 8 – 0.025 μM were prepared in 4:1 (v/v) 0.75 M MSG/DMSO (total 
volume 50 μL), and incubated with 0.2 mg/mL preformed microtubules.  Samples were 
processed and analyzed as described above for [14C]epothilone B.  A Ki value was determined 
for 6-epi-dictyostatin in the presence of [3H]discodermolide using the method described above 
for competitive studies utilizing [14C]epothilone B.   
 
Saturation Binding Experiments with [
3
H]5HPP-33 in the tubulin only system 
Determination of the Kd value for 5HPP-33 in the tubulin only system was performed as 
described previously.76  A stock solution of 45 mM [3H]5HPP-33 in DMSO was prepared and 
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from this samples of [3H]5HPP-33 between concentrations of 200-1 μM were prepared in 
DMSO. Reaction mixtures (total volume 0.32 mL) contained indicated concentration of 
[3H]5HPP-33, 1.0 mg/mL tubulin, 1% DMSO, and a buffer containing 0.1 M MES, pH 6.9, and 
0.5 mM MgCl2. Reaction mixtures were incubated for 30 min at 0 
oC, and 0.15 mL aliquots were 
applied in duplicate to Microcon centrifugal filtration units equipped with an Ultracel YM-30 
regenerated cellulose membranes.  The samples were spun at 14,000 x g for 12 min at 4 oC, and 
80 mL of the filtrate was used to determine concentration of free ligand by scintillation 
spectrometry.  The amount of non-specific binding was determined from samples prepared in the 
absence of tubulin and processed as described above.  Data was analyzed using the Hill equation 
that describes biphasic dose response: 
 
Bound = ((Bmax1 x [S]
n1)/(Kd1 + [S]
n1)) + ((Bmax2 x [S]
n2)/(Kd2 + [S]
n2)) 
 
Determination of [
3
H]5HPP-33 Binding to MAPs 
The binding of 5HPP-33 to MAPs was determined as described for the binding in the tubulin 
only system.  Samples of [3H]5HPP-33 were prepared at concentrations ranging from  50-200 
μM in DMSO.  The 0.32 mL reaction mixtures contained indicated concentrations of [3H]5HPP-
33, 2.0 mg/mL of MAPs, 1-3% DMSO, and 0.1 M MES, pH 6.9, containing 0.5 mM MgCl2.  
The mixtures were incubated for 30 min at room temperature, and processed in duplicate at room 
temperature as described above.  The binding of the compound to MAPs was determined from 
the amount of bound ligand in the presence of MAPs subtracted from the amount of bound 
ligand in the absence of MAPs. 
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Saturation Binding Experiment with [
3
H]5HPP-33 in the tubulin plus MAPs system 
The determination of a Kd value for 5HPP-33 in the presence of tubulin and MAPs was 
performed as described above.  Samples of [3H]5HPP-33 were prepared between concentrations 
of 200 - 1 μM in DMSO from a 50 mM stock solution.  The 0.32 mL reaction mixture contained 
the indicated concentrations of [3H]5HPP-33, 1.0 mg/mL tubulin, 0.75 mg/mL MAPs, 1% 
DMSO and 0.1 M MES, pH 6.9, containing 0.5 mM MgCl2.  The reaction mixture was incubated 
for 30 min at 0oC and processed as described above.  The data was analyzed using the Hill 
equation: 
Bound = (Bmax x [S]
n)/(Kd + [S]
n) 
 
[
3
H]Paclitaxel Competitive Inhibition Binding Assay 
The competitive inhibition assay was performed as described previously.77  To determine the 
ability of 5HPP-33 to displace paclitaxel from its binding site on the microtubule, a solution of 8 
μM [3H]paclitaxel solution was prepared in 0.75M MSG, pH 6.6. HPP-33 was prepared in 25% 
(v/v) DMSO and diluted into 0.75M MSG to give final concentrations of 4 μM and 20 μM.  
Discodermolide (4 μM) was prepared in the same mixture of DMSO and MSG and used as a 
positive control. The test agents (25 μL) were mixed with the [3H]paclitaxel (25 μL) and warmed 
to 37 °C.  Microtubules were preformed by incubating 0.75 M MSG, 0.2 mg/mL tubulin and 40 
μM ddGTP at 37 °C for 30 min. The preformed microtubules (50 μL) were added to the mixture 
of test agents and tracer, then incubated at 37 °C for 30 min. The reaction mixture was 
centrifuged at 14,000 rpm for 20 min at room temperature.  A 50 μL aliquot of supernatant was 
carefully removed and the amount of free [3H]paclitaxel was obtained using scintillation 
 33 
spectrometry.  Bound [3H]paclitaxel was calculated from the amount of total [3H]paclitaxel 
minus the amount of [3H]paclitaxel found in the supernatant.  Percent inhibition was calculated 
from bound values normalized to controls:   
% Inhibition = {[1-(bound test agents/bound control)]*100} 
 
[
3
H]Colchicine Percent Inhibition Binding Assay 
The [3H]colchicine percent inhibition binding assay was performed as described previously.71  
To determine the ability of 5HPP-33 to displace colchicine from its binding site, a reaction 
mixture containing 1 μM tubulin in 1M MSG, pH 6.6, containing 0.1 M glucose-1-phosphate, 1 
mM MgCl2, 1 mM GTP and 0.5 mg/mL bovine serum albumin was prepared.  The reaction 
mixture was incubated with 5 μM [3H]colchicine and test agent at 37 °C for 10 min.   
Podophyllotoxin at 5 μM was used as a positive control.   After incubation, the solution was 
filtered through two stacks of diethylaminoethyl (DEAE)-cellulose filters.  The filters trapped 
[3H]colchicine bound to the protein.  Each set of filters was immersed in scintillation cocktail 
and the radioactive counts determined using scintillation spectrometry.  Percent inhibition was 
calculated from the bound values normalized to the control values (with no inhibitor added).  
 
Radiolabeled Vinca Domain Binding and [
3
H]5HPP-33 Competitive Binding Assay 
The binding of radiolabeled ligand to tubulin was measured by centrifugal gel filtration as 
described by Bai et al. on 2 mL columns of sephadex G-50 (superfine).78  Each 0.32 mL reaction 
mixture contained 1.0 mg/mL (1.5 mg/mL for [3H]5HPP-33 binding assay) bovine brain tubulin 
in 0.1 M MES, pH 6.9, containing 0.5 mM MgCl2 that was treated with 5 μM inhibitor and 10 
μM [3H]vinblastine, [3H]dolastatin 10, or [3H]5HPP-33 predissolved in DMSO (final 
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concentration 1%, v/v).  The mixture was incubated for 30 min at room temperature. Aliquots 
(0.15 mL) of the reaction mixture were applied in duplicate to 2 mL Sephadex G-50 (superfine) 
columns preswollen with 0.1 M MES, pH 6.9, containing 0.5 mM MgCl2 and 1% DMSO.  The 
columns were centrifuged at 800xg for 4 min and the protein concentration in the effluent was 
determined using the bicinchoninic acid assay.  The amount of radiolabeled ligand bound to 
tubulin was determined using scintillation spectrometry.  Each value represents the mean + SD 
of four determinations.  The average stoichiometry of binding in the control reaction mixture was 
0.63 mole of [3H]vinblastine or [3H]dolastatin 10 per mole of tubulin.  The average stoichiometry 
of binding in the control reaction mixture was 0.011 mole of [3H]5HPP-33 per mole of tubulin. 
Inhibition was calculated as the percent difference relative to that of the control incubation with 
DMSO (i.e., without test agent -- assigned as 0% inhibition). 
 
2.3.8 Quantitative structure-activity relationships analyses 
Molecular modeling and quantitative structure activity relationships (QSAR) analyses were 
performed with the Cerius2 suite of programs (v. 4.05, Accelrys, Inc., San Diego, CA) utilizing 
the Merck Molecular Force Field/CHARMM, the adopted-basis Newton-Raphson approach to 
molecular mechanics minimizations in a dielectric field = 1, rigid body superimpositions based 
on atom similarities, the MOPAC93 suite of semi-empirical molecular orbital algorithms, and the 
genetic function approximation as previously described.40 
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3.0  CELL-BASED AND BIOCHEMICAL STRUCTURE ACTIVITY ANALYSES OF 
ANALOGUES OF THE MICROTUBULE STABILIZER DICTYOSTATIN 
3.1 ANALOGUES MADE PRIOR TO IDENTIFICATION OF THE ACTUAL 
STRUCTURE OF DICTYOSTATIN 
Prior to the elucidation of the exact structure of dictyostatin, the Curran group synthesized 
hybrids of discodermolide and dictyostatin.64  At this point, the only template for the structure of 
dicytostatin was Pettit’s partially assigned configuration as shown in Figure 9.79 The design of 
these early hybrids focused on constraining the discodermolide structure by hypothetical 
condensation of the lactone carbonyl with the amine.  Removal of the C6, C7, and C9 hydroxyl 
groups to form the analogue 6,7,9-deshydroxy-2,3,4,5,-tetrahydro-15Z,16-normethyldicytostatin 
was based on previous structure-activity relationship (SAR) data for discodermolide, which 
indicated that the omitted groups are not important for biological activity.64  SAR studies are 
applied to search for the minimum structural elements that in this case contribute to biological 
activity, cytotoxicity and retention of affinity to the taxoid site.80  7-epi-9-Deshydroxy-15Z,16-
normethyldictyostatin was biologically active with GI50 values, the amount of compound needed 
to inhibit growth inhibition by 50% as compared to control, of 1 μM in the breast and ovarian 
cancer cell lines tested. The analogues possessed a modest ability to compete with [3H]paclitaxel 
for its binding site. 
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In 2007, Paterson et al. expanded on Curran’s work by synthesizing a 
dictyostatin/discodermolide hybrid containing the full linear sequence (C2-C24) of 
discodermolide.81 Its three-dimensional structure nicely superimposes with that of 
discodermolide, but it does have GI50 values seven times higher than that of discodermolide in 
the cancer cell lines tested.   
Based on Pettit’s structure, the Curran’s group next step was to synthesize analogues to 
elucidate the structure of dictyostatin through the evaluation of biological activity.62 These 
analogues were 6,16-bis-epi-dictyostatin, 2E,6,14-bis-epi-dictyostatin, 6,14,19-tris-epi-
dicytostatin, and 2E,6,14,19-tris-epi-dicytostatin.  These analogues are shown in Figure 10.     
Figure 9.  Dictyostatin/discodermolide hybrids before and after the elucidation of the structure of  
(–)-dictyostatin. 
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These analogues were then tested to determine their biology and their potential as microtubule 
stabilizers.  Agents were tested in the ovarian cancer cell line 1A9 and in mutants of these cells 
that are resistant to paclitaxel.  The cell lines 1A9/Ptx10 (Phe270 to Val) and 1A9/Ptx22 (Ala364 
to Thr) contain mutations within the paclitaxel binding site on ?-tubulin.52  2E,6,14-epi-
dictyostatin is the only analogue that had any significant biological activity with GI50 values 
under 1 μM in all cell lines tested. Tubulin polymerization assays were performed in the 
presence and absence of MAPs to determine if the analogues induce polymerization and form 
cold stable polymer.  All of the analogues were inactive in this assay when compared to 
discodermolide and paclitaxel.  A competitive inhibition assay revealed that the analogues did 
not possess any ability to compete with [3H]paclitaxel for its binding site on ?-tubulin.  
 
Figure 10.  First generation analogues of dictyostatin based on Pettit's proposed structure. 
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3.2 SYNTHESIS OF DICTYOSTATIN ANALOGUES FOR STRUCTURE-ACTIVITY 
RELATIONSHIP STUDIES 
After the elucidation of the structure, synthesis and biological characterization of dictyostatin, 
the Curran and Paterson groups synthesized a number of analogues to provide clues into the SAR 
of dictyostastin.59-62, 64, 72, 82-84  
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Figure 11.  Dictyostatin analogues generated for use in SAR studies. 
 
The obvious way to begin the SAR studies of dictyostatin was to employ what was already 
known about discodermolide, due to the wealth of research done on its SAR, and exploit the key 
differences between the two compounds.  It is well known that changes to the C7 hydroxyl group 
of discodermolide do not change the cytotoxic behavior of the molecule, and that some 
modifications actually enhance activity.85, 86  C9 is the corresponding stereocenter in dictyostatin, 
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and Paterson et al. synthesized three analogues containing modifications there: 9-epi-
dictyostatin, 9-methoxydictyostatin and 9-normethyldicytostatin.87  Inversion of the stereocenter 
at C9 causes a significant drop in cytotoxicity in the cancer cell lines tested, which suggests that 
the C9 configuration is important to maintain biological activity.  The C9 methoxy analogue is 
almost as active as dictyostatin, with GI50 values in the low nanomolar range.  This analogue is 
active in the paclitaxel-resistant cell line NCI/ADR, which overexpresses the P-glycoprotein 
pump.   
From the SAR studies of discodermolide, it is known that the alkene at C13-14 is 
necessary for retention of biological activity, but reduction of the C8-C9 double bond produces a 
compound that retains activity.88  Using this information, Paterson et al. designed 10,11-
dihydrodictyostatin, hypothesizing that this simplification would not alter biological activity.84  
This analogue is more active than discodermolide in the pancreatic and colon cancer cell lines 
tested, but does not retain activity in the NCI/ADR cell line.  This suggests that the C10-C11 
alkene is necessary for dictyostatin to avoid becoming a substrate for the P-gylcoprotein pump.   
The C1-C9 chain is one of the main structural differences between the two natural 
products, and dictyostatin analogues designed to examine this region were epimers at C6, C7 and 
C9, and C2:3 geometric isomers.  From discodermolide SAR studies, it is has been established 
that removal of the C14 methyl group does not decrease cytotoxicity in the cancer cell lines 
tested. When the 14-normethyldiscodermolide was tested in paclitaxel resistant cell lines, 
however, cytotoxicity was greatly decreased (IC50 values in the micromolar range).
89  From this 
finding, the Curran and Paterson groups were prompted to synthesize 16-normethydictyostatin 
(Paterson’s group refers to this compound as 16-desmethydictyostatin.83,87  Curran’s group 
expanded on this work with the synthesis of a series of C16 analogues.  Since discodermolide is 
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an open chain analogue of the macrolactone of discodermolide, a 16-epi open chain methyl ester 
analogue was also synthesized.  Discodermolide possesses a C13:14 Z-alkene, which is missing 
in dictyostatin, and an analogue was synthesized containing a C15:16 Z-alkene.  In theses 
syntheses, two analogues with dictyostatin’s macrolactone contracted to 20 members were also 
made (the isodicytostatins).61 
Due to the loss in cytoxic activity of 14-normethyldicodermolide analogue in 1A9 cell 
containing the Phe270 mutation to Val, it can be hypothesized that changes to the C16 region of 
dictyostatin would also be lead to a loss in cytotoxicity.  Although changes to the C9 stereocenter 
of dictyostatin had already been investigated changes to the C6 and C7 stereocenters had not.  It 
can be hypothesized that changes to this region will not affect the biological activity because 
signication changes to the lactone region of discodermolide are well tolerated as long as the 
lactone remains intact.88   To examine in detail the effects of these targeted structural modifications 
on biological activity and the interaction with the proposed target, quantitative multiparameter 
immunofluorescence assays were used to measure mitotic arrest and nuclear morphology in 
conjunction with in vitro tubulin assembly and displacement studies using the taxoid site-binding 
agents epothilone B and discodermolide.  During this evaluation, the saturation binding kinetics of 
epothilone B and discodermolide were also characterized.  Quantitative structure-activity 
relationship (QSAR) and molecular modeling studies were employed to gain insight into the 
correlation between the structure of dictyostatin and its analogues to their cytotoxic effects. 
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3.3 CELLULAR EFFECTS OF DICTYOSTATIN AND ITS ANALOGUES 
DETERMINED BY MULTIPARAMETER IMMUNOFLOURESCENCE MICROSCOPY 
Multiparameter high content analyses, a tool to acquire, manage and retrieve information from 
multiparametric experiments to yield information about the activity and spatial regulation of 
multiple targets in cells, were used to characterize the responses of tumor cells to the agents.61  
This work was performed in Dr. Andreas Vogt’s lab in the Department of Pharmacology, School 
of Medicine at the University of Pittsburgh.  This assay provided information on the effects of 
such agents on microtubule mass, histone H3 phosphorylation and nuclear morphology.  The 
procedure is described in detail in Chapter 2.   In short, HeLa cells were grown in 384-well 
microtiter plates and were treated with each compound for 21 h.  The cells were fixed, their 
nuclei stained with Hoechst 33342, permeabilized, microtubules and phosphohistone H3 were 
immunostained, and FITC- and Cy3-conjugated secondary antibodies were added. From the 
Hoechst staining, a nuclear mask was generated defining the area used to determine microtubule 
mass and percentage of histone H3 phosphorylation.  Microtubule mass was determined from the 
cells average (FITC) pixel intensity in cells.  The percentage of histone H3 phoshorylation was 
determined from the number of cells with a higher pixel intensity for Cy3 than the average plus 
one standard deviation seen within vehicle-treated cells.  Using a range of concentration of test 
agents, the minimum detectable effective concentration (MDEC) was determined.  The MDEC 
value is the minimum concentration at which each agent causes a response in excess of vehicle-
treated control cells.70  The MDECs for nuclear condensation, histone H3 phosphorylation, and 
changes in microtubule morphology for dictyostatin and its analogues are shown in Table 1.  As 
a measure of toxicity, cell densities were measured as Hoechst 33342-stained nuclei per imaging 
field.  The toxicity measurements in HeLa cells were consistent with those reported for other 
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human cancer cell lines examined with the 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxy- 
phenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay, where the decrease in absorbance at 490 
nm was seen after cells treated with drug were exposed to the mitochondrially-activated dye 
MTS along with the electron acceptor N-methylphenazine.61, 62 
Toxicity measurements and the MDEC values generated from this initial screen allowed 
for the quick assessment of the analogues’ abilities to increase histone H3 phosphorylation, cause 
cell death, and increase microtubule mass.  Increases in the levels of histone H3 phosphorylation 
and microtubule mass are indicators of more cells undergoing mitosis compared to control, and 
are fundamental markers of microtubule perturbing agents.  As shown from the values in Table 
1, The S configuration of the C16 methyl group, C2:3Z geometry, and a 22-membered ring were 
essential for retention of biological activity.61  From this data, the four most potent analogues 
were chosen for further evaluation: 6-epi-dictyostatin, 7-epi-dictyostatin, 16-
normethyldictyostatin and 15Z,16-normethyldictyostatin. 
Table 1. Potency of dictyostatin and its analogues against HeLa cells using multiparameter 
fluorescence microscopy. 
 EC50 (nM)  MDEC 
(nM) 
 
Compound Cell 
Density 
Nuclear 
Conden-
sation 
Mitotic 
Index 
Micro-
tubule 
Mass 
Paclitaxel 10.4 + 1.9 3.9 + 2.0 3.5 + 1.2 5.2 + 0.4 
Dictyostatin 9.2 + 6.6 3.9 + 1.0 5.8 + 1.5 5.4 + 1.9 
16-epi-dictyostatin 1872 + 449 1132 + 66 1032 + 173 1278 + 181 
16-epi-open chain dictyostatin >5000 >5000 >5000 >5000 
16-epi-isodictyostatin >5000 >5000 >5000 >5000 
16-normethyldictyostatin 34.7 + 6.2 23.7 + 8.8 24.1 + 5.4 25.0 + 9.0 
7-epi-dictyostatin 17.5 + 1.9 7.7 + 2.1 8.5 + 3.9 8.0 + 3.2 
6-epi-dictyostatin 8.9 + 2.7 4.5 + 1.9 3.8 + 2.8 4.0 + 0.9 
2E,3,15Z,16-normethyldictyostatin 896 + 135 738 + 214 520 + 95 647 + 106 
15Z,16-normethyldictyostatin 23.9 + 15.5 12.6 + 5.2 9.3 + 0.2 11.7 + 1.7 
9-epi-15Z,16-normethyldictyostatin >5000 >5000 >5000 >5000 
15Z,16-normethylisodictyostatin >5000 >5000 >5000 >5000 
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Figure 12 illustrates the mitotic phenotype observed after treatment of cells with the four 
test agents.  Equipotent concentrations were picked to illustrate similar phenotypes for each test 
agent as compared to control cells (treated with DMSO only). Cells were immunostained for ?-
tubulin (green) and phospho-histone H3, and the nuclei were stained with Hoechst (blue).  
Figure 12.  Immunofluorescence images of HeLa cells treated with dictyostatin and analogues.   
HeLa cells were treated with vehicle (A) or equipotent concentrations of dictyostatin (B), 6-epi-
dictyostatin(C), 7-epi-dictyostatin (D), 15Z,16-normethyldictyostatin (E), or 16-normethyldictyostatin 
(F).  The nucleus was stained with Hoechst (blue) and microtubules (green), and phosphohistone H3 
(red) were stained with fluorescently labeled secondary antibodies 
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Vehicle-treated cells had highly organized microtubules and a low percentage of mitotic cells. 
All compounds tested caused a heterogenous response of microtubule disorganization, increased 
numbers of phospho-histone H3 positive cells, enhanced chromatin condensation and nuclear 
fragmentation. Images shown are representative from a single experiment that was repeated 
twice with each experiment yielding similar results. 
Cells treated with dictyostatin (2B, 31 nM) showed microtubule bundling and abnormal 
spindle formation, characteristic of cells treated with a microtubule stabilizer.  Panels C-F 
represent the images obtained when HeLa cells were treated with 6-epi-dictyostatin (2C 7.8 nM), 
7-epi-dictyostatin (2D, 15.6 nM), 15Z,16-normethyldictyostatin (2E, 19.5 nM) or 16-
normethyldictyostatin (2F, 31 nM).  All compounds produced microtubule bundling and 
abnormal spindle formation. These compounds caused increased mitotic indices, condensed 
nuclei, an increased microtubule mass, and a loss of cell density at nanomolar concentrations.  6-
epi-Dictyostatin and 7-epi-dictyostatin affected all parameters at concentrations comparable to 
dictyostatin, whereas the 16-normethyl derivatives had less activity. It was a surprise to find that 
15Z,16-normethyldictyostatin was more potent in all aspects than 16-normethyldictyostatin, 
because both compounds had a loss at C16 of the methyl group.  Thus, high-content analysis 
provided a rapid and efficient means to generate cellular SAR data on mitotic arrest, microtubule 
morphology, and cytotoxicity.  It demonstrated that structural modifications in the 6, 7, 15, and 
16 positions did not significantly reduce compound activity in cells.  
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3.4 DETERMINATION OF THE ABILITY OF DICTYOSTATIN AND ITS 
ANALOGS TO INDUCE TUBULIN ASSEMBLY AND FORM COLD STABLE 
POLYMER 
 
Under the hypothesis that the potent analoges would retain the ability to hypernucleate and 
stabilize polymer a microtubule polymerization assay was performed. In vitro tubulin assembly 
assays were performed with the agents under conditions in which polymerization does not occur 
in the absence of test agents and compared their activities to that of paclitaxel (?) as shown in 
Figure 13.   Tubulin polymerization assays register microtubule formation as a change in 
absorbance, which is a consequence of the polymer scattering light as it is formed.   
 
 
 
 
 
 
 
 
 
In a temperature-controlled spectrophotometer reading absorbance at 350 nm every 15 sec, 
isolated bovine brain tubulin was cooled to 2.5 °C and test agents were added at time zero to a 
final concentration of 10 ?M. The test agent-containing tubulin solutions were rapidly warmed to 
30 °C to induce assembly and, after 20 min at 30 °C, cooled back to 2.5 °C.  To ensure that 
Figure 13. Tubulin polymerization assay to determine effects of dictyostatin and its  
analogues on tubulin assembly. 
 
? - paclitaxel 
? - 4% DMSO 
? - dictyostatin 
? - 7-epi-dictyostatin 
? - 6-epi-dictyostatin 
? - 15Z,16-normethyldictyostatin 
? - 16-normethyldictyostatin 
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polymer was formed only in the presence of test agents, 4% DMSO (?) was used as a negative 
control.  Three agents were more active than the positive control paclitaxel (?).  Dictyostatin 
(?) was the most potent compound in terms of nucleating and polymerizing ability, closely 
followed by 7-epi-dictyostatin (?) and 6-epi-dictyostatin (?).  There were some slight 
differences between the C6 and C7 epimers.  7-epi-Dictyostatin caused polymer to form more 
rapidly than did 6-epi-dictyostatin, but the extent of polymerization caused by 6-epi-dictyostatin 
was greater.  The polymer formed with 6-epi-dictyostatin appeared more stable against cold 
depolymerization than the polymer from 7-epi-dictyostatin or dictyostatin itself.  The nucleating 
and polymerizing activities of 15Z,16-normethyldictyostatin (?) and 16-normethyldictyostatin 
(?) were reduced, but still comparable to those of paclitaxel.   Polymer formed in the presence 
of these two compounds was cold stable.  
 From this study it was concluded that 6-epi and 7-epi-dictyostatin retain microtubule 
stabilizing and hypernucleating abilities.  There was a slight loss in these ablities with the C16 
analogues but there activity was still comparable to paclitaxel.  This data provides evidence that 
the analogues of dictyostatin are working in the same manner as the parent compound.   
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3.5 CHARACTERIZATION OF [14C]EPOTHILONE B SATURATION BINDING TO 
MICROTUBULES 
As discussed in the introduction, dictyostatin and the four analogues have the ability to displace 
radiolabeled paclitaxel from preformed microtubules in vitro. 63 It was hypothesized that based 
on previous evidence that epothilone B  can competively compete with [3H]paclitaxel for its site, 
dictyostatin and its analogues should competitively compete with epothilone B. These 
preliminary observations were expanded upon by performing detailed binding kinetics using 
[14C]epothilone B.   
   
 
 
 
 
 
 
 
 
 
Epothilone B has an even higher affinity to the taxoid site on tubulin than does paclitaxel.91  The 
saturation binding kinetics of [14C]epothilone B has not been reported.  Isolated tubulin was 
incubated with radiolabeled [14C]epothilone B and the amount of protein-bound radioactivity 
quantified as described in  Chapter 2. A version of the saturation binding equation that was 
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Figure 14. Saturation binding data for the binding of [14C]epothilone B to microtubules. 
? - Total bound 
? - Non-specific bound 
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modified to account for ligand depletion, known as Swillen’s equation, was employed to 
determine the Kd value for the binding of [
14C]epothilone B to microtubules.  As shown in Figure 
14, fitting the data using Swillen’s modified equation, which simultaneously fits total binding 
and nonspecific binding, yielded a Kd value for epothilone B of 36.04 + 1.58 nM. The x-axis 
shows the total [14C]epothilone B added and the y-axis the amount of ligand bound. Nine 
concentrations in the range of 5 nM to 2 ?M of the radiolabeled compound epothilone B (?) 
were used to determine the Kd value.  Nonspecific binding was determined by competition with 8 
?M discodermolide (?).  Each data point shown is the mean of three independent experiments ± 
S.D.  The extent of non-specific binding was estimated by measuring the amount of 
[14C]epothilone B bound to microtubules in the presence of 8 ?M discodermolide.  As the Kd 
value of paclitaxel is reported to be between 0.06-0.1 μM and since the relative affinities of 
agents for the taxoid site follows the order paclitaxel < epothilone B <  discodermolide, the Kd 
value obtained in these experiments for epothilone B was considered reasonable and 
acceptable.80 
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3.6 DETERMINATION OF INHIBITION CONSTANTS FOR DICTYOSTATIN AND 
ITS ANALOGUES UTILIZING [14C]EPOTHILONE B IN COMPETITION 
EXPERIMENTS 
The Ki values for dictyostatin and its analogues were determined using the modified Hanes 
analysis method of Edler et al.75  The method uses the free concentration of radioligand instead 
of the total concentration, and also accounts for the free inhibitor concentrations. Concentrations 
used ranged from 0.25-12 μM for the inhibitors dictyostatin, 6-epi-dictyostatin, and 7-epi-
dictyostatin.  For the less potent inhibitors, concentrations ranged from 1-50 μM.  
[14C]Epothilone B concentrations were 1, 2, 2.5 and 3 μM for all experiments. As shown in 
Figure 15, plots of free concentration of [14C]epothilone B versus free substrate divided the 
fractional saturation (instead of enzyme velocity) for 6-epi-dictyostatin yielded plots of parallel 
lines with slopes close to 1.   
 
 
 
 
 
 
 
 
 
 
 
Figure 15. Hanes plot of the inhibition of binding of [14C]epothilone B to microtubules by 6-epi-
dictyostatin. 
Free [14C]Epothilone B (μM) 
S
/?
 ? - no inhibitor 
?- 1.6 μM 6-epi-dictyostatin 
?- 0.8 μM 6-epi-dictyostatin 
?- 0.3 μM 6-epi-dictyostatin 
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The fractional saturation was calculated from the total amount of tracer added minus the 
free concentration of tracer counted. Experiments were performed as described in Chapter 2.  Kis 
were determined from the x-intercept equal to –(Kd(1+[I]/Ki).  The legend is as follows:  (?), no 
inhibitor μM; (?), 1.6 μM 6-epi-dictyostatin; (?), 0.8 μM 6-epi-dictyostatin; and (?), 0.3 μM 
6-epi-dictyostatin.  The Kd value for [
14C]epothilone B, determined from the negative intercept 
on the x-axis, was 50 + 20 nM, close to the value obtained from the saturation experiments.  As 
shown in Table 2, 16-normethyldictyostatin and 15Z,16-normethyldictyostatin gave the highest 
Ki values, reflecting their reduced binding affinity.   
 
      Table 2.  Equilibrium inhibition constants for dicytostatin and its analogues calculated from        
      Hanes analysis of [14C]epothilone B competition experiments. 
Compound Ki (μM) 
15Z,16-normethyldictyostatin 4.47 + 0.28 
16-normethyldictyostatin  4.55 + 0.41 
6-epi-dictyostatin 0.48 + 0.07 
7-epi-dictyostatin 0.93 + 0.31 
dictyostatin 0.07 + 0.02 
 
The Ki value for 15Z,16-normethyldictyostatin was 4.47 + 0.28 μM and the value for 16-
normethyldictyostatin was 4.55 + 0.41.  This data correlates with the tubulin polymerization 
data, which showed that 16-normethydictyostatin and 15Z,16-normethyldictyostatin were the 
least potent of the compounds in nucleation and microtubule stabilization.  Dictyostatin, as 
expected, showed the highest affinity for the taxoid site with a Ki value of 70 + 20 nM. 
Surprisingly although 6-epi and 7-epi dictyostatin were either as good or better in the high 
content screening assay, these compounds had substantially lower affinities with Ki values of 
480 + 70 nM and 930 + 310 nM, respectively. It was concluded, that dictyostatin was a potent 
competitive inhibitor of  [14C]epothilone B binding to ?-tubulin.  As seen by their slightly lower 
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Ki values, the 6-epi-and 7-epi-dictyostatin analogues retained their affinity for the taxoid site.  
The C16 analogues showed a loss in affinity for binding to isolated tubulin and this was in 
concordance with the tubulin polymerization study.  All analogues showed a competitive nature 
to the inhibition of [14C]epothilone binding and the slopes of the parallel lines indicated one site 
competition.   
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3.7 CHARACTERIZATION OF [3H]DISCODERMOLIDE SATURATION BINDING 
TO MICROTUBULES 
An attempt was made to elucidate the binding of [3H]discodermolide to microtubules. 
Dictyostatin is the structural cousin of discodermolide and the kinetics of dicytostatin binding to 
the microtubule might be analogous to those of discodermolide. The saturation binding kinetics 
of [3H]discodermolide has not been previously determined.  As described in Chapter 2, 8 μM-25 
nM of [3H]discodermolide were incubated with 0.2 mg/mL preformed microtubules for 30 min, 
centrifuged for 30 min, and then supernatant removed for scintillation spectrometry.  The 
concentration of free ligand was calculated from the amount of radioactivity in the supernatant, 
and from this value the total amount of [3H]discodermolide bound could be determined.  The 
modified Swillen’s equation was employed to determine the Kd value for discodermolide binding 
to microtubules as shown in Figure 16.   
 
 
 
 
 
 
 
 
 
 
Figure 16.  Saturation binding data for the binding of [3H]discodermolide to microtubules. 
? - Total bound  
 
? - Total Bound 
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A Kd value of 0.207 + 0.088 μM was obtained, but this value does not accurately reflect what is 
reported in the literature. This value is higher than obtained for both paclitaxel and epothilone B.  
From the competitive binding experiments performed in the Day lab and in the literature, it is 
generally agreed that affinity for the taxoid site goes in the order discodermolide > epothilone B 
> paclitaxel.63  One reason for the discrepancy in the Kd value for [
3H]discodermolide stems 
from the inablility to determine its non-specific binding.  Non-specific binding is the amount of 
radioligand bound to sites other than of the specific site of interest.  It is usually determined by 
adding a high concentration (~100 times the Kd) of a known competitor to completely saturate 
any potential binding sites.73  Bound radioligand is measured under these conditions for each 
concentration, and is substracted from the total bound to give the amount of specifically bound to 
the site of interest.  Unfortunately, discodermolide has such a high affinity for the taxoid site that 
I could not find an inhibitor with enough solubility and affinity to appreciably alter the binding 
of this radioligand.  It is thus not possible with the current supply of inhibitors to accurately 
determine non-specific binding for [3H]discodermolide. 
Although there was not a non-specific binding determination, it is possible that the Kd 
value obtained could be close to the actual value for [3H]discodermolide binding.   The data from 
competitive binding assays indicates that there is not a known agent that can effectively displace 
[3H]discodermolide from its binding site.92,93  There is a possibility that discodermolide’s 
binding to ?-tubulin produces a conformational change within the protein that either reduces or 
prevents the binding of other taxoid site agents.  It is possible then that the competitors’ 
ineffectiveness in displacing [3H]discodermolide from its binding site is due to this 
conformational change and not to a  higher affinity for the taxoid site. 
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3.8 DETERMINATION OF AN INHIBITION CONSTANT FOR 6-EPI-
DICTYOSTATIN UTILIZING [3H]DISCODERMOLIDE 
Although accurate an accurate Kd value could not be determined for discodermolide in the 
previous binding experiments, Hanes analyses were still employed to determine an inhibition 
constant for 6-epi-dictyostatin as a competitive inhibitor of [3H]discodermolide binding. As 
shown by the almost parallel lines in Figure 17, 6-epi-dictyostatin was a competitive inhibitor of 
[3H]discodermolide binding to the microtubule with slopes close to 1.  The concentrations of 6-
epi-dictyostatin used in this experiment ranged from 0.25-12 μM and the concentrations of 
[3H]discodermolide were 0.25 μM, 0.5 μM, 1.0 μM and 2.0 μM.   
 
 
 
 
 
 
 
 
 
Unlike the competitive binding experiments with [14C]epothilone B, there was not significant 
depletion of the inhibitor, 6-epi-dictyostatin, because the concentrations of 6-epi-dictyostatin 
used in this assay did not significantly inhibit the binding of discodermolide. The fractional 
saturation was calculated from the total amount of tracer added minus the free concentration of 
tracer counted. A Ki value was determined from the x-intercept equal to –(Kd(1+[I]/Ki).  The 
? - no inhibitor 
?- 1.0 μM 6-epi-dictyostatin 
?- 2.0 μM 6-epi-dictyostatin 
?- 4.0 μM 6-epi-dictyostatin 
 
 
Free [3H]Discodermolide (μM) 
S
/?
 
Figure 17. Hanes plot of the inhibition of binding of [3H]discodermolide to microtubules by 6-epi-
dictyostatin. 
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legend is as follows:  (?), no inhibitor μM; (?), 1.0 μM 6-epi-dictyostatin; (?), 2.0 μM 6-epi-
dictyostatin; and (?), 4.0 μM 6-epi-dictyostatin.  The Ki value for 6-epi-dictyostatin was 
calculated to be 2.38 + 0.13 μM.  The Kd value for [3H]discodermolide, determined from the 
negative intercept on the x-axis, was 68  nM.  
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3.9 QUANTITATIVE STRUCTURE-ACTIVITY ANALYSES 
Using the NMR-derived solution structure of discodermolide as a template, molecular models of 
dictyostatin, its analogues, discodermolide, and 14-normethyldiscodermolide were built.94  This 
work was performed in the Day lab by Ms. Kia Montgomery.  The lowest energy conformers of 
the models were found by exhaustive molecular mechanics minimization, and all models were 
superimposed onto that of discodermolide.  The only structures that did not superimpose well 
were 2E,15Z,16-normethyldictyostatin and the 20-member iso analogues as shown in Figure 18.  
A large number of thermodynamic, electronic, steric, and linear free energy descriptors were 
then calculated for each model.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18. Image generated by superimposing the structures of dictyostatin, the 12 analogues of 
dictyostatin, and 14-normethydiscodermolide (sticks) onto the solution NMR structure of 
discodermolide (bars). 
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At this point a decision was made as to the biological metric to use for the “activity” portion 
of the QSAR.  The 50% growth inhibitory concentrations (GI50) of the compounds against 
human ovarian carcinoma 1A9 cells, which express wild type ?-tubulins, were chosen for this 
purpose.  Because the number of descriptors far exceeded the number of compounds studied, the 
genetic function approximation (GFA) was used to fit the smallest number of descriptors. In the 
GFA approach, a random population of equations of given length is generated, their fitness is 
determined by a number of statistical metrics (in particular Friedman’s lack-of-fit and R2), and 
the equations are “evolved” by inclusions of combinations from two of the best equations 
(parents).39  This process is reiterated (each iteration is termed a “generation”) with a given 
frequency of “mutation” (random descriptor loss or use) incorporated into each iteration until the 
best descriptors and QSAR equations with the best statistical metrics are found. The five best 
equations were: 
 
(1) –(logGI50) = –0.017328-0.41287(rotable bonds) + 0.091723 (HFMOPAC) – 
0.223325(HF) + 0.0611096(dipoleMAG) 
(2) –(logGI50) = –26.5019 + 0.03692(area) – 0.328785(rotable bonds) – 0.04374(HF) + 
0.924229(dipoleMOPAC) 
(3) –(log GI50) = –26.3842 + 0.1088(area) + 1.31599 (dipoleMOPAC) – 0.353032(MR) + 
0.654779(logP) 
(4) –(logGI50) = 1.694349 – 0.305704(rotable bonds) – 0.135425(HF) + 
0.605182(dipoleMOPAC) – 0.053736(HFMOPAC) 
(5) –(logGI50) = –48.6935 + 0.200571(MR) – 0.270041(rotable bonds) + 
1.27617(dipoleMOPAC) + 0.117247(area) 
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where rotable bonds is the number of single bonds contained within the molecule, HF is the heat 
of formation (the change in enthalpy for forming a molecule from its constituent atoms) 
calculated with MNDO or with PM3 in MOPAC, log P is the calculated octanol-water partition 
coefficient, MR is molar refractivity, area describes the Van der Waals area of a molecule, and 
dipole is the dipole moment of the molecule.   
The most significant descriptors in each equation were determined using a “leave-one 
(descriptor)-out” exercise.39 This entailed calculating the activity with one of the descriptors set 
to zero, and then calculating the deviation of the resulting value from the predicted activity when 
all descriptors were used.  From this exercise, the contribution of each descriptor was 
determined.  For equations 2, 3 and 5, the most important contributors to activity were area and 
molar refractivity.  For equations 1 and 4, the most important descriptor was the heat of 
formation. 
The predicted activity values generated from these equations were plotted versus the actual 
activity in 1A9 ovarian cancer cells to determine the correlations.  As shown in Figure 19, a plot 
of the predicted values generated from equation 1 versus actual values lead to a correlation 
coefficient (R2) of 0.943.  Values for the R2 of the other four equations were also >0.93.  
 
 
 
 
 
 
Figure 19.  Graph of predicted activity from QSAR analyses versus actual values for dictyostatin, 
its analogues, and 14-normethyldiscodermolide. 
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3.10 DISCUSSION 
Several conclusions were reached about the SAR for dictyostatin based on the compounds’ 
effects on HeLa cell proliferation, histone H3 histone phosphorylation, microtubule mass, and 
nuclear morphology.  The importance of the 22-membered ring was proven by the inactivity of 
the 20-membered analogues 16-epi-isodictyostatin and 15Z,16-normethylisodictyostatin. If the 
C16 methyl group is present, it must be in the S-configuration, which is seen by the complete 
loss in activity of the 16-epi-analogue. C2:3Z geometry is also necessary. The most potent 
analogues from this screen were 6-epi-dictyostatin, 7-epi-dictyostatin, 15Z,16-
normethyldictyostatin and 16-normethyldictyostatin. Only minor differences in the compounds’ 
cellular activities were observed, although 6-epi-dictyostatin and the parent compound were the 
most active agents in all experiments. From these and previous experiments performed in the 
Day lab, and in conjunction with Paterson’s work, a rather complete picture of dictyostatin’s 
SAR can be depicted as shown in Figure 20. 
 
 
  
 
 
 
 
 
 
Figure 20.  SAR for dictyostatin. 
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Although qualitatively the rank order of cellular activities correlated with the in vitro activities, 
there were some differences in the compounds’ abilities to cause in vitro tubulin assembly and 
binding site affinity studies.  It is noteworthy that the 16-normethyl derivatives 15Z,16-
normethyldictyostatin and 16-normethyldictyostatin had an almost 5-fold higher Ki values 
compared with the C6 and C7 epimers.  This is consistent with the hypothesis that the C16 
methyl group is important in binding to the taxoid site through a key interaction with Phe270 on 
?-tubulin.   16-Normethyldictyostatin has a reduced potency in the paclitaxel-resistant 
1A9/PTX10 ovarian cancer cell line, which has a Phe270 to Val point mutation in the taxoid 
binding site.  This is consistent the binding data, where the lower affinity observed in 
competition experiments with 15Z,16-normethyldictyostatin and 16-normethyldictyostatin can be 
attributed to the loss of the favorable interaction of the C16 methyl group of dictyostatin with the 
Phe270 in ?-tubulin. 
As observed from a similar loss in potency in 1A9/PTX10 lines, the interaction between 
the benzoyloxy group of paclitaxel and Phe270 of ?-tubulin is important for activity. 52, 83  The 
importance of the interaction between Phe270 and methyl substituents in dictyostatin, epothilone 
B and discodermolide is now becoming well established.  Molecular modeling studies performed 
by Xia et al. show the C14 methyl group of discodermolide could be positioned in a favorable 
interaction with Phe270 in the hydrophobic binding pocket of the taxoid site.92   The importance 
of this interaction has been confirmed by in the decrease of nucleating ability in tubulin 
polymerization assays with 14-normethyldictyostatin performed in our laboratory (data not 
shown).  Reese et al. have recently reported on the NMR-derived binding mode of epothilone A 
to the tubulin heterodimer.95  A two dimensional NMR-derived binding model of epothilone A to 
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the tubulin heterodimer suggests that the increased potency of epothilone B over epothilone A is 
due to the interaction of the C12 methyl with Phe270. 
As shown by the QSAR studies, the size of the molecule (area and molar refractivity) is 
the most significant contributor to cytostatic activity against 1A9 ovarian cancer cells.  A loss of 
a methyl substituent would certainly lead to a decrease in the van der Waals area of the molecule 
and according to calculations, lead to a decrease in activity.  Molar refractivity is a measure of 
the volume occupied by the molecule.   It is dependent on a number of factors such as molecular 
weight, refractive index and density.  This descriptor relates to the London dispersive forces that 
act in the drug-receptor interaction.96 Again, 16-normethyldictyostatin and 15Z,16-
normethyldictyostatin would be expected to have molar refractivities differing from those of 
dictyostatin and its C6 epimer, whose molar refractivities are identical.  
Canales et al. recently published a report on the bound conformation of both dictyostatin 
and discodermolide to microtubules polymerized in the presence of the nucleotide analogue, 
guanosine 5’-?,?-methylenetriphosphate (GMPCPP).97 This model predicts both discodermolide 
and dictyostatin to overlap with almost the entire paclitaxel skeleton except for the 
phenylisoserine side chain.  This model does explain the ability of discodermolide and 
dictyostatin to stabilize microtubules by binding to the M loop on ?-tubulin and enhance the 
lateral contacts between protofilaments. 
There is a problem with this model of discodermolide and dictyostatin binding to ?-
tubulin.  The first is the observation that GMPCPP forms different microtubule structures under 
different buffer conditions.98 This could account for differences in the orientation of these 
compounds in the microtubules formed in the presence of this compounds and those within cells.   
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Changes to the C6 and C7 stereocenters of dictyostatin were explored because they are 
present in the structure of discodermolide as its C4 and C5 carbons; part of its delta lactone ring. 
The multiparameter immunofluourescence studies with 6-epi-dictyostatin and 7-epi-dictyostatin 
showed that these analogues produced microtubule bundling and abnormal spindle formation at 
nanomolar concentrations.  Their ability to produce these various cellular responses was 
observed at lower concentrations than that required with dictyostatin.  Although there was a 
slight loss in nucleation ability in tubulin polymerization assays, these compounds retained their 
ability to induce assembly of microtubules and to form cold stable polymer.  In addition, both 
compounds still had a high affinity for the taxoid site on ?-tubulin with the Ki values obtained in 
competition experiments with [14C]epothilone B of 480 nM and 930 nM for 6-epi-dictyostatin 
and 7-epi-dictyostatin, respectively.  From these experiments, it can be said that changes to this 
area is not only well tolerated, but lead to no loss in potency in vivo.  
The saturation binding kinetics of epothilone B were characterized.  One important 
assumption that is made to ease calculations in equilibrium binding is that only a small amount 
of substrate binds to its target leaving the relative amount of free substrate concentration 
unchanged.  Ligand depletion occurs if more than 10% of the substrate binds to the protein.73  
When ligand depletion occurs, this assumption is invalidated and can, if not taken into account, 
cause errors in data analysis. Ligand depletion is a common problem in the centrifugation assay 
commonly used to determine the binding kinetics of microtubule stabilizing agents. For this 
reason, the saturation binding data were analyzed using the modified Swillen’s equation as 
described in Chapter 2, which not only accounts for ligand depletion but also fits total binding 
and nonspecific binding simultaneously. Fitting the nonspecific and total binding data 
simultaneously allows for calculation of free ligand, and defines nonspecific binding as a 
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constant fraction of the free ligand concentration. The Kd value obtained using this analysis was 
reasonable using previous competitive inhibition studies as a measure of the affinity of 
epothilone B for the taxoid site.35, 63 
The binding kinetics of dictyostatin and its analogues were determined with radiolabeled 
epothilone B. Epothilones are competitive inhibitors of paclitaxel binding, and the epothilones 
retain activity against almost all known paclitaxel resistant cell lines; the exception is the 
1A9/A8 line, which possesses a mutation of Arg 282 to Gln in ?-tubulin and is resistant to both 
paclitaxel and epothilone B.53  All of the agents tested here were found to be competitive 
inhibitors of epothilone B’s binding site on tubulin polymer, implying that dictyostatin and 
epothilone B share a common binding site on microtubules.  As in the saturation binding 
experiments with with [14C]epothilone B, significant ligand depletion was observed in the 
competition experiments.  The modified Hanes analysis was employed as described in Chapter 2 
and accounts for the free concentration of radiolabeled tracer and that of the free inhibitor.  
QSAR modeling led to a number of equations that will be useful in predicting the activity 
of new analogues of dictyostatin in cells.  The four descriptors employed in these equations are 
all variables that can be easily manipulated by a synthetic chemist.   
It is not surprising that the structures of dicytostatin and a number of its analogues 
superimposed well on the NMR-determined solution structure of discodermolide (which, in fact, 
closely matches the structure determined by X-ray crystallography).99  In fact, Sanchez-Pedregal 
recently published a superimposition of the U-shaped configuration of discodermolide bound to 
tubulin onto that of dictyostatin and noted that they are superimposable.100  As can be correlated 
with its significant decrease in activity, 2E,3,15Z,16-normethyldictyostatin did not superimpose 
well onto the structure of dictyostatin.  
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In conclusion, a number of potent analogues of the microtubule stabilizer dictyostatin 
have been tested to determine the cellular responses they evoke, their effects on tubulin 
polymerization, and their ability to inhibit binding of [14C]epothilone B to microtubules.  During 
this process, the saturation binding kinetics of epothilone B was characterized, and epothilone B 
demonstrated great affinity for the taxoid site.  Dictytostatin and its analogues are all competitive 
inhibitors of [14C]epothilone B binding as demonstrated by Hanes analysis.  These experiments 
have further led to the conclusio that dictyostatin, discodermolide, epothilone B, and paclitaxel 
have favorable interactions with Phe270 within the taxoid binding site on ?-tubulin.  A change to 
the configuration of the stereocenter at C6 or C7 of dictyostatin is well tolerated.  From this 
work, it can be conjectured that for good efficacy against cancer cell lines, all future analogues of 
dictyostatin must retain the ability to interact with Phe270 on ?-tubulin, and that this interaction 
is important to the efficacy of many other taxoid site-binding, microtubule-stabilizing 
compounds.  The characterization of the 6-epi-dictyostatin analogue as a potent microtubule-
stabilizing agent has motive the gram scale synthesis for use in preclinical studies.  Our QSAR 
analyses led to a number of equations that will be useful in guiding the production of and 
predicting the cellular activity of new, more potent dictyostatin analogues.  The four descriptors 
employed in these equations are all variables that can be easily be manipulated by a medicinal 
chemist.   
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4.0  GENERATION OF A RADIOLABELED VERSION OF A THALIDOMIDE 
ANALOGUE TO DETERMINE THE KINETICS OF A NEW MICROTUBULE 
PERTURBING AGENT 
4.1 AN ANALOGUE OF THALIDOMIDE, 5HPP-33 (2-(2,6-
DIISOPROPYLPHENYL)-5-HYDROXY-1H-ISOINDOLE-1,3-DIONE) 
Thalidomide was first prescribed to pregnant women in the 1950s as a sedative and 
antiemetic.101, 102  It was quickly withdrawn from the market in 1961 due to reports of limb 
growth defects in babies of mothers who were given thalidomide during pregnancy.  Interest in 
thalidomide was renewed due to the fact that it is useful in the treatment of various 
dermatological and inflammatory conditions.103  It was approved in the United States for the 
treatment of a serious dermatological reaction associated with leprosy.  Folkman et al. found that 
thalidomide prevents angiogenesis, elucidating the underlying cause of the limb growth 
defects.104  Angiogenesis is the formation of new blood vessels and is important in the growth 
and metastasis of tumor cells in vivo.105  This revelation has led to the prospect of thalidomide as 
a potential chemotherapeutic agent. 
  Thalidomide has been found to be effective in the treatment of multiple myeloma.  
Multiple myeloma is a devasting cancer of the bone marrow and results in the malignancy of the 
plasma cells and B cells.104  Thalidomide's efficacy against this disease stems from a number of 
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mechanisms.  Thalidomide is a potent inhibitor of the cytokine TNF-?.106  TNF-? is one of the 
major cytokines involved in the mediation of innate immune responses.  The most important role 
of TNF-? is its function in stimulating inflammatory and immune responses to a variety of 
foreign bodies (e.g., microbial infections).   The inhibition of TNF-? expression within the bone 
marrow decreases the growth and formation of new blood vessels that nurture the malignant 
cells.  Thalidomide is also known to increase T-cell proliferation, thereby causing the release of 
certain cytokines.107    These cytokines activate natural killer cells, which attack and lyse the 
cancerous cells.  Reports also suggest that thalidomide decreases the expression of vascular 
endothelial growth factor (VEGF), a pro-angiogenic growth factor.108   
 The multiple actions of thalidomide have inspired many researchers to design analogues 
of the drug with hopes of creating a compound with enhanced activity.  The focus of most of 
these evaluations of the analogues has been on the immunomodulatory functions of 
thalidomide.109, 110  Hashimoto et al. originally designed thalidomide analogues in an attempt to 
enhance the regulatory mechanism of TNF-? production.111  Replacement of the glutaramide 
ring of thalidomide with an aromatic ring led to the production of active analogues.112, 113  
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4.2 5HPP-33 AS A MICROTUBULE PERTURBING AGENT 
Inatsuki et al. reported on a readily synthesizable thalidomide analogue containing a 5C-hydroxy 
group and an isopropylphenylpthalimide structure as a potent antiproliferative agent with an IC50 
of 5 μM against human leukemia cells.114  The authors named this compound 5HPP-33.  The 
authors provided evidence for the mechanism by which proliferation is inhibited. Evidence 
suggested that the compound inhibits the formation of microtubules and binds to tubulin dimers 
rather than to microtubule polymer.  It was not clear at this time where the compound binds on 
the dimer or the mechanism of the inhibition of polymerization.  
The characterization of this small molecule as a potential microtubule perturbing agent 
prompted its synthesis in Dr. Pui-Kai Li’s lab at The Ohio State University.66 The synthesis is 
shown in Scheme 1.  5HPP-33 94 was prepared by the condensation of 2,6-diisopropylaniline (1) 
with 5-hydroxyphthalic acid (2).   
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The objectives of this study were to fully characterize 5HPP-33 as a microtubule perturbing 
agent and potential chemotherapeutic agent.  A number of biochemical and cellular studies were 
performed to reach this goal.  The antiproliferative effects of 5HPP-33 were determined in a 
number of cancer cell lines.  Flow cytometry experiments were performed to determine the 
effects of 5HPP-33 on cell cycle progression.  Tubulin polymerization assays were performed in 
the presence and absence of microtubule associated proteins (MAPs) to determine the effects of 
5HPP-33 on polymer formation.  Electron microscopy pictures were taken to visualize the 
Scheme 1. Synthesis of 5HPP-33 
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phenotype of polymer formed in the presence of 5HPP-33.  Competitive inhibition experiments 
were performed to determine if 5HPP-33 could compete for known microtubule perturbing 
agents at their respective binding sites on the tubulin heterodimer.  Finally, a radiolabeled 
analogue of 5HPP-33 was synthesized and the kinetics of its interaction with tubulin were 
determined to establish a Kd value in the presence and absence of MAPs.   
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4.3 EVALUATION OF THE EFFECTS OF 5HPP-33 ON CELLULAR 
PROLIFERATION AND THE CELL CYCLE 
4.3.1 5HPP-33 is a potent antiproliferative agent against many tumor cell lines in vitro 
Li et al. have shown 5HPP-33 to have antiproliferative activity against many different cell lines, 
with GI50 concentrations as shown in Table 3.
66  5HPP-33 inhibits the proliferation of estrogen-
dependent (MCF-7), estrogen-independent (MDA-MB231) breast cancer cells, colon cancer cells 
(HT-29), bladder cancer cells (TCCSUP), ovarian carcinoma cells (1A9), and androgen-
dependent (LNCaP) as well as androgen-independent prostate cancer cells (DU-145 and PC-3). 
The GI50 values represent the means of three experiments with triplicate determinations. The 
GI50 values of the agent were in the low micromolar range against every cell line tested.  
Thalidomide was not nearly as active as 5HPP-33 and exhibited GI50 values of > 300 μM. 
 
Table 3.  Determination of 50% growth inhibition concentrations of 5HPP-33 and thalidomide 
against various cancer cell lines. 
Cell Type 5HPP-33 (GI50)  (μM) Thalidomide (μM) 
MCF-7 6.2 + 0.41 >300 
MDA-MB231 5.2 + 0.32 >300 
HT-29 5.09 + 1.41 >300 
TCCSUP 6.52 + 0.97 >300 
LNCaP 1.65 + 0.21 >300 
DU-145 5.74 + 0.23 >300 
PC-3 8.28 + 0.81 >300 
1A9 2.1 + 0.1 Not Tested 
 
5HPP-33 also maintains its activity against cell lines expressing the P-glycoprotein pump and 
containing mutations within the binding site of paclitaxel on ?-tubulin as shown in Tables 4 and 
5. The P-glycoprotein pump confers resistance to multiple cell types through overexpression of 
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the ABCB1 (a.k.a. MDR1 = multidrug resistance) gene.115 The cell lines used were transfected 
with retroviral vectors expressing either of two forms of P-glycoprotein pump:  wild type (G185) 
or a point mutant (V185) that alters the selectivity of the pump. Values given are the average of 
two separate experiments.  RR is relative resistance (ratio of the GI50 of transfected cells/ GI50 of 
the non-transfected cells).  Paclitaxel is a known substrate of the P-glycoprotein pump and this is 
seen by the 57-fold decrease in its potency within the cell line expressing the wild type pump 
(Table 4).116  Colchicine and 5HPP-33 retain their respective potencies in these cell lines and 
with only a 6.7-fold and 1.2-fold decrease, respectively, in GI50 values.  When the compounds 
were tested in the NIH 3T3 cell line expressing the mutated P-glycoprotein pump, 5HPP-33 is 
the only drug that retains potency in this cell line.  This is compared to paclitaxel and colchicine, 
where potency is dramatically reduced.   
 
Table 4.  Effects of 5HPP-33, paclitaxel, and colchicine on the NIH 3T3 cell lines. 
Drug NIH 3T3 NIH3T3G185 NIH3T3V185 
 GI50 
(μM) 
RR GI50 
(μM) 
RR GI50 
(μM) 
RR 
5HPP-33 3 1 3.6 1.2 4.5 1.5 
Paclitaxel 0.04 1 2.28 57 1 25 
Colchicine 0.06 1 0.4 6.7 5.2 87 
 
Table 5.  Effect of 5HPP-33 in 1A9 ovarian carcinoma cells. 
 
 
 
The effects of 5HPP-33 in 1A9 ovarian carcinoma cells and derived lines were tested.  
1A9PTX10 contains a mutation at nucleotide 810, which replaces the phenylalanine at position 
Drug 1A9 Parental PTX10 (F270V) PTX22 (A364T) 
 GI50 
(?M) 
RR Relative Resistance Relative Resistance 
5HPP-33 2.1 + 0.1 1 1.1 0.7 
Paclitaxel 0.002* 1 24 24 
Vinblastine 0.0035* 1 0.5 0.4 
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270 with valine on the ?-tubulin subunit within the paclitaxel binding site.52  1A9PTX22 
contains a mutation at nucleotide 1092, which changes the alanine at position 364 to threonine. 
Values for the GI50s of paclitaxel and vinblastine were taken from Giannakakou et al.
52  
Paclitaxel has a GI50 value in the low nanomolar range in the parental cell line, but this value 
increases 24-fold in the resistant cell lines.  Vinblastine retains activity in both the parental and 
resistant cell lines.  These results are not surprising because vinblastine binds to a site on the 
tubulin heterodimer different from that of paclitaxel.28  5HPP-33 retains potency in all cell lines 
tested suggesting that its binding site is not identical to that of paclitaxel.   
4.3.2 The effect of 5HPP-33 on the cell cycle. 
Flow cytometry is used to detect and measure the fluorescence or absorbance signals of cells as 
they flow in a liquid stream through a beam of light.117  Li et al. used flow cytometry to 
quantitate the number of 1A9 cells in the G1, S and G2/M phases of the cell cycle.
66  The cells 
were stained with the DNA intercalating agent propidium iodide, which provides a way of 
determining DNA content.  The cells were also treated with the mitosis-specific antibody TG3.  
This provided a means of determining the amount of cells in the M phase over the G2 phase
118.  
The results of this study are shown in Figure 21.   
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The bottom graphs in Figure 21 are histograms of the number of cells counted versus fluorescent 
intensity of propidium iodide staining.  These provide easy visualization of the proportion of 
cells in each phase upon drug treatment at the various concentrations indicated compared to the 
control.  The upper graphs are the two-parameter analyses of fluorescence intensity of TG3 
staining versus fluorescence intensity of propidium iodide.  These graphs allow for the 
calculation of the percentage cells in M phase.  The percentage of cells in each phase after the 
indicated treatment of drug is presented in Table 6.  After treatment with of 1A9 cells with 10 
nM paclitaxel, 81% of cells are in the G2/M phase and 64% are in M phase.  A comparison can 
be made to the 10 μM 5HPP-33 treatment, where 96% of cells are in G2/M phase and 70% are in 
Figure 21.  Flow cytometric analysis of 1AP cells treated with the indicated  
concentrations of 5HPP-33 and paclitaxel. 
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M phase.  It can now be hypothesized that the antiproliferative activity of 10 μM 5HPP-33 can 
be attributed to the agent’s ability to block cells in the G2/M phase.  At very high concentrations 
of 5HPP-33, this effect is lessened, likely due to death (and disappearance from the analysis) of 
the cells blocked in G2/M, and apparent appearance of a greater number of cells in G1 and S.   
 
   Table 6.  Calculation of percentage of 1A9 cells in the G2/M and M phase from 
   two-parameter flow cytometric analysis. 
Compound % G2/M % M phase 
Control 13.5 4.7 
10 nM Paclitaxel 81 64 
3 μM  5HPP-33 38 24 
10 μM  5HPP-33 96 70 
30 μM  5HPP-33 68 18 
100 μM 5HPP-33 47 19 
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4.4 EFFECTS OF 5HPP-33 ON TUBULIN POLYMERIZATION AND 
VISUALIZATION OF POLYMER FORMED USING ELECTRON MICROSCOPY 
4.4.1 Tubulin polymerization assays 
Tubulin polymerization in vitro is stimulated under different conditions and can be quantified 
using a spectrophotometer that measures polymerization as a change in turbidity, which is 
measured as a change in absorbance at ? = 350 nm.63  Due to the large amount of tubulin found 
in the mammalian brain, tubulin can be purified from fresh bovine brain in high yield.67  Tubulin 
polymerization assays are performed under a variety of conditions to gain insight into the 
interactions of potential antimitotic agents with purified tubulin.119 The two most common 
conditions to monitor tubulin assembly are the glutamate system and the microtubule-associated 
proteins (MAPs) system.  Microtubule associated proteins bind to the microtubule lattice and 
help to stabilize the heterodimer interactions.1   Polymerization can be simulated in vitro with the 
mixture of MAPs, purified tubulin and GTP in a buffer warmed to 37 oC in a cuvette.120   High 
concentrations of glutamate salts can induce tubulin assembly, take the place of MAPs, and act 
as a buffer.  Although GTP is still necessary to induce polymerization, the glutamate system is 
easier to use over the MAPs system because the need for an additional purified protein is 
negated. Potent inducers of microtubule polymerization, such as discodermolide and dictyostatin, 
can induce formation of microtubules without the addition of MAPs or GTP.63 Also the 
glutamate system alleviates the possibility of the compound binding to MAPs.  A major 
limitation to the spectrophotometrically-quantified tubulin polymerization assays is that the exact 
structure of the polymer formed cannot be directly determined.  There are antimitotic compounds 
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that form aberrant polymer, but this is registered on the spectrophotometer no differently from 
microtubule formation.78 
 
4.4.2 The effects of 5HPP-33 on tubulin polymerization in the MAPs system 
The tubulin polymerization assay was first performed in 0.1 M MES, pH 6.9, containing 1.0 
mg/mL tubulin, 0.75 mg/mL MAPs and 400 μM GTP, and the indicated concentrations of 5HPP-
33 in vehicle.  The temperature of the cuvettes was tightly controlled throughout this experiment 
from 0 – 30 oC as shown in Figure 22.   
  
 
 
 
 
 
 
  
 
 
 
 
Figure 22.  Tubulin polymerization assay to determine the effects of 5HPP-33 on 
tubulin assembly in the MAPs system. 
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5HPP-33 completely inhibited tubulin polymerization at 10 μM.  The concentration at which 
5HPP-33 inhibited tubulin polymerization by 50% as compared to control (IC50) was calculated 
to be 6.77 μM. 
 The addition of exogenous Mg2+ to tubulin polymerization assays enhances tubulin 
assembly; 0.05 M MgCl2 was therefore added to the MAPs system. Magnesium cation binds to 
tubulin in a 1:1 ratio and has been shown to improve GTP’s ability to bind to the exchangeable 
site.121  The results of the experiment are shown in Figure 23.   
 
 
 
 
 
 
 
 
 
 
The presence of magnesium cation decreased the ability of 5HPP-33 to inhibit polymerization.  
As shown in Figure 23 in the MAP’s system without exogenously added Mg2+, a concentration 
of 20 ?M 5HPP-33 completely inhibited tubulin polymerization.   At 20 ?M, 5HPP-33 in the 
system containing Mg2+ tubulin polymerization was still able to occur, but almost complete 
inhibition of the reaction did occur at 40 ?M 5HPP-33.  It was concluded from this experiment, 
that the addition of Mg2+ was overcoming 5HPP-33’s ability to inhibit microtubule 
Figure 23.  Effect of 5HPP-33 on tubulin polymerization in the MAPs system with addition of 
0.05 M MgCl2. 
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polymerization.  This experiment provided further evidence that 5HPP-33 is a microtubule 
inhibitor.   
4.4.3 The effects of 5HPP-33 on tubulin polymerization in the glutamate system  
It was first noted by Hamel et al. that organic anions, such as monosodium glutamate (MSG), 
could be used to induce tubulin polymerization.122 MSG is the buffer preferred for the long-term 
storage of purified tubulin.67  For assembly to occur with purified tubulin in MSG, the 
temperature must be above 20 oC and GTP must be added. A standard protocol is usually 
performed in MSG to assess potential tubulin polymerization inhibitory activity.  The method for 
the assay is described in the Materials and Methods section.  Briefly, tubulin, MSG, and 
indicated drug concentrations in 4% DMSO are pre-incubated for 15 min, then placed into 
cuvettes cooled to ~0 oC, and 400 μM GTP is added.  As shown in Figure 24, 5HPP-33 did not 
inhibit polymerization at 5 μM but seemed to induce it. 
 
 
  
 
 
 
 
 
I 
 
Figure 24.  Effect of 5HPP-33 on tubulin assembly in the MSG system. 
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At a concentration of 10 μM, 5HPP-33 increased the extent of assembly, which is the last 
turbidity reading at 30 oC, and forms cold stable polymer.  This formation of cold stable polymer 
is also seen at 5 μM 5HPP-33, but the extent of assembly and reaction rate was reduced at this 
concentration. 
In an attempt to determine an IC50 for 5HPP-33 in the MSG system, the concentration of 
GTP was lowered from 400 μM to 100 μM.   As shown in Figure 25, 2.5 μM 5HPP-33 inhibits 
tubulin assembly by 41 %.   
 
 
 
 
 
 
 
 
 
 
Figure 25.  Effect of 5HPP-33 on tubulin assembly in the MSG system containing 100 μM GTP. 
 
Although the reaction rate was decreased as compared to vehicle only control, there was polymer 
formed in the presence of 5μM 5HPP-33.  This extent of polymer formation was even greater in 
the presence of 10 μM 5HPP-33.  The polymer formed appeared to be stable to cold 
disassembly.  Examination of these tubulin polymerization graphs shows it is unlikely that 
5HPP-33 was causing the formation of tubulin polymer.  The inhibition of assembly indicates 
that microtubules are likely not forming in either system, but that an aberrant polymer formation 
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with a concentration dependent increase in the MSG system was occurring.  The only true test of 
this was to visualize the polymer formed using electron microscopy.   
4.4.4 Electron microscopy analysis of the effects of 5HPP-33 on tubulin assembly 
Electron microscopy has made it possible to visualize particular structures within the cell and is 
commonly utilized to display the effect of microtubule perturbing agents on tubulin assembly. 
Transmission electron microscopy, where the images are generated from the absorbance of 
electrons, is typically used to visualize microtubule.123  Specimens are prepared by taking sample 
directly out of the cuvettes used in the tubulin polymerizations assays, placing a 1 μL drop on a 
copper grid, and staining with a heavy metal salt.  The heavy metal is needed to visualize the 
image because the greater the atomic number in the specimen, the larger the percentage of 
electrons scattered, and the greater the resolution.124   
With compounds that stabilize and promote microtubule formation such as paclitaxel and 
discodermolide, microtubule lengths measured from electron micrographs give an estimate of the 
nucleating ability of the compound.63  For compounds that inhibit microtubule formation, 
aberrant polymer formation can be visualized with electron microscopy.  Such is the case with 
the vinca domain/depsipeptide site binding agent dolastatin 10, which causes the formation of 
rings and tightly coiled spiral aggregates.125  The formation of these structures causes a change in 
turbidity in tubulin polymerization assays.   
The polymer formed in the presence of 5HPP-33 in the two systems was visualized by 
taking aliquots from the polymerization assays at 30 oC. A concentration of 5HPP-33 of 20 μM 
was chosen for the evaluation of the polymer because this is the temperature and concentration at 
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which 5HPP-33 completely inhibited polymerization in the MAPs system.  Figure 26 shows the 
electron micrographs of polymer obtained at 30 oC in the MSG system.   
 
 
 
 
 
 
 
 
 
Panel A is the negative control that shows normal microtubule formation in the presence of no 
drug.  The protofilaments that make up the microtubule can be visualized at 20000x 
magnification.  It is clear from Panel B that at 30 °C microtubule formation did not occur.  
5HPP-33 in the MSG system appeared to induce tubulin to form aggregates of spirals and rings, 
which is the cause of the turbidity development in the cuvettes during the polymerization assay.  
The average ring outer diameter of the rings was 35.8 + 6.7 nm.  Panel C shows a 60000x 
magnification of the aberrant polymer that was formed.   
 The electron micrographs obtained from the MSG system showed no signs of 
microtubule formation in the presence of this modifier, and the reason for the increase in 
turbidity during the polymerization assay.  Electron micrographs were also taken from 
experiments done with the MAPs system at 30 oC and are shown in Figure 27. 
 
Figure 26.  Electron microscopy images of the effects of 5HPP-33 on tubulin polymerizaiton  
in the MSG system. 
100 nm 
     A 
100 nm 
B 
20 nm 
C 
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Panels B and C show that an aberrant polymer was still formed, but was mostly in the 
form of small rings instead of the large aggregated polymer that was observed in the MSG 
system. This could account for the difference in the results for the tubulin polymerization 
reactions between the two systems. The diameter of the rings could not be measured from the 
reactions with 20 μM 5HPP-33 in the MAPs due to poor resolution.  In the MSG system, the 
aggregation reaction seemed to be much more aggressive than in the MAPs system.  This 
phenomenon has been seen before with other microtubule perturbing agents such as dolastatin 
10, where there is a major change in morphology and aggregation in different systems.44  Unlike 
5HPP-33, the turbidity and morphology change with dolastatin 10 occurs in the MAPs system 
and not the MSG system.  
From the images obtained by electron microscopy in both systems, it is clear that the 
major mechanism by which 5HPP-33 perturbs microtubules is by inhibition of polymer 
formation.  The next step was to determine where on the tubulin heterodimer 5HPP-33 might 
bind, and if it competes with other known microtubule perturbing agents.  
 
500 nm 
A 
100 nm 
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100 nm 
C 
Figure 27.  Electron microscopy images of the effects of 5HPP-33 on tubulin polymerization  
in the MAPs system. 
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4.5 EFFECTS OF 5HPP-33 ON THE BINDING OF RADIOLABELED 
MICROTUBULE PERTURBING AGENTS TO TUBULIN OR TUBULIN POLYMER 
Percent inhibition of radiolabeled ligand by a normoisotopic competitor are used to quickly 
determine if compounds of interest can compete, either competitively or non-competively, for 
the binding site of a previously characterized microtubule perturbing agent. 63  These assay 
provides a quick method to assess the ability of new agents and analogues to bind to tubulin or 
tubulin polymer, and to determine if further analyses are needed.  
4.5.1 Effect of 5HPP-33 on the binding of [3H]paclitaxel to tubulin polymer 
Paclitaxel binds to the ? subunit of tubulin when in the form of the microtubule, and stabilizes 
the lateral interactions between heterodimers.  To determine if 5HPP-33 can compete with 
[3H]paclitaxel for its binding site on the microtubule, a competition assay was performed as 
described in the Materials and Methods section. Briefly, 2 μM [3H]paclitaxel, inhibitor, and 0.2 
mg/mL preformed microtubules in 0.75 M MSG, pH 6.9, were incubated for 30 min at 37 oC, 
centrifuged for 30 min, and the amount of free [3H]paclitaxel in the supernatant determined.  
Discodermolide was used as the positive control because of its known ability to compete for the 
taxoid binding site.63, 77 
   
Table 7.  Percent inhibition by 5HPP-33 of the binding of [3H]paclitaxel to tubulin   
            polymer. 
Compound Concentration (μM) % Inhibition + S.D. 
5HPP-33 4 –10 + 0.4% 
5HPP-33 20 –10 + 0.5% 
Discodermolide 4 86 + 3% 
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The percent inhibition values are the average of three separate experiments.  As shown in Table 
7, at 5HPP-33 concentrations of 2- and 10- fold higher than [3H]paclitaxel, no competition for 
the taxoid binding site on the microtubule was observed.  This is in contrast to 4 μM 
discodermolide, which completely inhibited binding of 2 μM [3H]paclitaxel.   
4.5.2 Effect of 5HPP-33 on the binding of [3H]colchicine to tubulin 
The colchicine binding site is located on ?-tubulin near the ?/? heterodimer interface.26  
Colchicine binds to tubulin and causes a slow conformational change, which inhibits the 
polymerization of microtubules.28  To see if 5HPP-33 binds to the same site as colchicine and 
other related agents, a percent inhibition assay was performed.  In this assay, one separates 
bound tubulin from free competitor by filtration through diethylaminoethyl (DEAE) cellulose 
filters.  The binding of colchicine to tubulin is stabilized in this assay by the addition of 
exogenous salts and organics acids.126 
 
Table 8.  Effects of 5HPP-33 on [3H]colchicine binding to tubulin 
Compound % Inhibition + S.D. 
5 μM 5HPP-33 –10 + 7 
25 μM 5HPP-33 –64 + 1 
5 μM Podophyllotoxin 75 + 18 
 
 
As shown in Table 8, 5HPP-33 actually enhanced the binding of [3H]colchicine to tubulin 
instead of inhibiting it.  The percent inhibition values listed are the average of duplicate 
experiments + S.D.  This is compared to the positive control, podophyllotoxin, which inhibited 
the binding of [3H]colchicine by 75%.   
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4.5.3 Effects of 5HPP-33 on the binding of vinca domain and peptide/depsipeptide site 
agents to tubulin 
The microtubule perturbing agents that bind to the vinca domain and the closely associated 
peptide/depsipeptide site on ? tubulin are inhibitors of polymerization and can inhibit GTP 
hydrolysis.44  These binding sites are near the exchangeable nucleotide site on the protein and, 
when bound, cause a block in the longitudinal interactions between tubulin heterodimers. 
Dolastatin 10 and the vinca alkaloids cause aberrant polymer formation at superstoichiometric 
concentrations in polymerization assays in the MAPs system.  As shown above, 5HPP-33 also 
causes aberrant polymer formation, which was visualized by electron microscopy.  Percent 
inhibition assays were performed with [3H]dolastatin 10 and [3H]vinblastine to determine if 
5HPP-33 binds to the peptide/depsipeptide site or the vinca domain.  These two compounds were 
chosen because they are known to be non-competitive for each other’s respective binding sites.   
The results from the [3H]dolastatin 10 competition assay are presented in Table 9.  The 
percent inhibition values represent the average + S.D. of two independent experiments.  5HPP-33 
did not compete for [3H]dolastatin 10’s binding site at any concentration tested.   
 
Table 9.  Effect of 5HPP-33 on [3H]dolastatin 10 binding to tubulin. 
Compound % Inhibition + S.D. 
5 μM 5HPP-33 –7 + 4 
50 μM 5HPP-33 –1 + 5 
5 μM Vincristine 17 + 5 
5 μM Colchicine –11 + 10 
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5HPP-33 also did not show any appreciable inhibition of  [3H]vinblastine binding to its site on ?-
tubulin as shown in Table 10.  Vincristine, an analogue of vinblastine, was used as a positive 
control, and it inhibited binding of the radiotracer by 62%.   
 
Table 10.  Effect of 5HPP-33 on [3H]vinblastine binding to tubulin 
 
 
 
 
 
 
 
 
 
 
 
 
 
Compound % Inhibition 
5 μM 5HPP-33 10 + 7 
100 μM 5HPP-33 3 + 3 
5 μM Vincristine 62 + 2 
5 μM Colchicine –3 + 4 
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4.6 SYNTHESIS AND PURIFICATION OF A RADIOLABELED ANALOGUE OF 
5HPP-33 
The competitive percent inhibition data suggested that 5HPP-33 may bind to a novel site on the 
tubulin heterodimer.  To gain further insight into the binding site of 5HPP-33 and its kinetics, a 
radiolabeled analogue was synthesized. The synthesis was performed in three steps, which are 
shown in Scheme 2.   
H2N H2N
I
4
PhCH2NEt3ICl2
NaHCO3
MeOH/CH2Cl2
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HO
O
OH
O
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O
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N
O
O
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In the first step, benzyltriethylammonium dichloroiodate was utilized to selectively iodinate 
the para position of 2,6-diisopropylaniline 1.  Condensation of 4-hydroxyphthalic acid 2 and the 
aryl iodide 4 yielded iodo-5HPP-33 5 ,which was hydrogenolyzed using 10% Pd/C as the 
catalyst and tritium gas to form [3H]5HPP-33 6.  Tritium gas was supplied by a Trisorber® 
tritiation manifold.  This method allows for a measured amount of tritium to be released, and 
subsequent uptake of any unused gas without release into the surroundings of the experiment.   
The total radioactivity yielded was 1.20 mCi. 
Scheme 2.  Radiosynthesis of [3H]5HPP-33 
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The determination of chemical and radioactive purity of the compound was performed by 
HPLC analysis with both UV and scintillation detection as detailed in the Materials and Methods 
section.  The specific activity of [3H]5HPP-33 from this procedure was 26.78 Ci/mmol.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 88 
4.7 BINDING OF [3H]5HPP-33 TO TUBULIN AND COMPETITIVE INHIBITION 
ANALYSES 
4.7.1 Interactions of [3H]5HPP-33 with purified tubulin 
To determine the mechanism by which [3H]5HPP-33 interacts with purified bovine brain tubulin, 
concentrations between 1-200 μM were incubated with 1.0 mg/mL tubulin at 0 oC for 30 min.  
Bound ligand was separated from free using a Millipore ultrafiltration apparatus, and the filtrate 
was used for scintillation spectrometry.  The results of this experiment are presented in Figure 
29, and each data point is the average of two experiments + S.D.  [3H]5HPP-33 did not exhibit 
normal saturation binding kinetics, and attempts to fit the data using a non linear equation that 
fits one site or two- site binding yielded no results.   As previously described in Chapter 2, Kd 
values were calculated using the Hill equation to fit the observed biphasic sigmoidal kinetics 
shown in Figure 28.   
 
 
 
 
 
 
 
 
 
Figure 28.  Determination of [3H]5HPP-33 binding to tubulin. 
? - Specific bound 
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Two Kd values were obtained, 78.6 + 3.5 μM and 137.5 + 10.5 μM for a high and a low 
affinity site, respectively. The Hill slopes were calculated to be ~2 and ~6 for the high and low 
affinity Kd values, respectively.  As shown in Figure 29, the Scatchard plot for [
3H]5HPP-33 
binding to tubulin exhibited a downward curvature.  Such a curvature is reminiscent of enzyme 
systems displaying positive cooperativity.  The plot appears to be two downward facing curves, 
which could indicate two binding sites.   
 
 
 
 
 
 
 
 
 
 
4.7.2 Interactions of [3H]5HPP-33 with Microtubule Associated Proteins 
The possibility that 5HPP-33 interacts with MAPs and diminishes the aggregation reaction of 
tubulin dimmers was tested by incubating 2.0 mg/mL of MAPs with various concentrations of 
[3H]5HPP-33. Figure 30 shows the results of this experiment using three concentrations of 
[3H]5HPP-33.  Higher concentrations could not be tested because of solubility issues with 
Figure 29.  Scatchard plot of [3H]5HPP-33 binding to tubulin 
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[3H]5HPP-33 (insoluble in the assay conditions at concentrations > 200 μM), which prevented 
the determination of a Kd value.   
 
 
 
 
 
 
 
 
 
 
 
The values reported are the average of two experiments + S.D.  At a concentration of 50 μM, 
[3H]5HPP-33 binding to 2.0 mg/mL MAPs could be detected, and binding increased in a 
concentration dependent manner.  
4.7.3 Effect of MAPs on [3H]5HPP-33 binding to the tubulin heterodimer 
The conditions performed in the tubulin polymerization assay were simulated in the binding 
assay to test the effects of the presence of MAPs on [3H]5HPP-33 binding to tubulin 
heterodimer.  Briefly, various concentrations of [3H]5HPP-33 were incubated with 0.75 mg/mL 
MAPs and 1.0 mg/mL tubulin at 0oC for 30 min.  The reaction mixture was then transferred to 
the ultrafiltration apparatus and the amount of free [3H]5HPP-33 was determined by scintillation 
Figure 30.  [3H]5HPP-33 binding to 2.0 mg/mL MAPs 
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spectrometry.  The results of this experiment are presented in Figure 31.  The binding data was 
analyzed as described previously for the tubulin only data set.  The high affinity Kd value for the 
MAPs plus tubulin binding set, was not significantly different from that obtained in the tubulin 
only system, yielding a value of 67.5 + 12.4 μM, but a low affinity Kd value could not be 
determined.  The Hill slope was calculated to be ~3 using GraphPad Prism.   
 
 
 
 
 
 
 
 
The Scatchard plot for this binding data is presented in Figure 32.  This plot is a 
downward parabola that is characteristic of both self-associating and positive cooperativity 
systems.  This plot does not have the two downward curves that were seen in the tubulin only 
system in Figure 30. 
 
Figure 31.  Saturation binding data for [3H]5HPP-33 in the MAPs plus tubulin system 
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4.7.4   Competitive inhibition assays with [3H]5HPP-33 
It is conceivable that 5HPP-33 competes with known microtubule perturbing agents, even though 
this could not be detected in any of the previous binding experiments.  There are two possible 
explanations for this phenomenon.  One is that the low affinity of 5HPP-33 for the tubulin 
heterodimer made it impossible to detect any significant competition, or the wrong form of 
tubulin was used in the competition assay (i.e., soluble tubulin versus preformed microtubules).  
To determine if this was the case, a competitive inhibition assay utilizing gel filtration to separate 
bound ligand from free was utilized.  Table 11 presents the results of this assay, in which 10 μM 
[3H]5HPP-33, 1.5 mg/mL tubulin and various concentrations of inhibitor were used. 
Table 11. Competitive inhibition experiments with [3H]5HPP-33 
Compound % Inhibition + S.D. 
5 μM Vinblastine –6 + 10 
5 μM Colcemid –15 + 11 
50 μM Colcemid –42 + 8 
5 μM Paclitaxel 0 + 3 
50 μM Paclitaxel 18 + 7 
 
Figure 32.  Scatchard plot of binding data in tubulin plus MAPs system 
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Colcemid, an colchicine analogue, failed to inhibit binding of [3H]5HPP-33 at all 
concentrations tested.127  There was not any appreciable inhibition of binding using 5 μM 
vinblastine.  Paclitaxel at a concentration of 50 ?M inhibited the binding of [3H]5HPP-33 by 
18%.  This inhibition is probably due to the formation of microtubules in the presence of 
paclitaxel, which causes the loss of the soluble tubulin.  It was reported by Inatsuki et al. that 
5HPP-33 binds to soluble tubulin over microtubules.114  
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4.8 DISCUSSION 
5HPP-33 is a small, structurally simple molecule, with antiproliferative activity in the low 
micromolar range against a number of cancer cell lines. Flow cytometric analyses show that 10 
μM 5HPP-33 blocks cells in the G2/M phase of the cell cycle.66  Tubulin polymerization assays 
showed 5HPP-33 to have mixed effects on microtubule polymerization dynamics.  In the tubulin 
polymerization system utilizing MSG, 5HPP-33 appeared to induce polymerization and stabilize 
polymer against cold depolymerization.  In the MAPs system, 5HPP-33 produced the opposite 
effect, and at a concentration of 10 ?M completely inhibited microtubule polymerization.  To 
unravel this discrepancy, electron microscropy was used to characterize the polymer formed in 
both systems.  The electron microscopy pictures explained the differences between the tubulin 
polymerization assays.  From the images obtained, it is clear that microtubules are not being 
formed in either system and that 5HPP-33 causes an aberrant polymer formation.  This polymer 
was an aggregation of rings and spirals, and aggregation was lessened in the MAPs system.  The 
lessened aggregation explains the appearance of the tubulin polymerization graph.  At this point 
in time, the exact mechanism for the heightened aggregation in the presence of MSG was not 
known.    
The rings and spirals formed in the presence of 5HPP-33 is reminiscent of the vinca 
domain binding agents, such as dolastatin 10 and the vinca alkaloids.44  Numerous percent 
inhibition assays with radiolabeled vinca domain binding compounds were performed, but 
5HPP-33 failed to compete with any of these agents.  5HPP-33 failed to compete with 
[3H]colchicine and [3H]paclitaxel for their respective binding sites on tubulin heterodimer. A 
five-fold excess of paclitaxel seems to compete for the 5HPP-33 binding site on the tubulin 
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dimer.  This inhibition is probably due to the formation of microtubules in the presence of 
paclitaxel but not to actual competition between the two compounds.   
The inability of 5HPP-33 to compete for the binding site of many known microtubule 
perturbing agents, and the lessening of aggregation seen in the MAPs system tubulin 
polymerization graphs prompted the radiosynthesis of [3H]5HPP-33.  It is possible that the loss 
in aggregation observed in the MAPs system is due to the binding of 5HPP-33 to MAPs, and this 
hypothesis was tested using [3H]5HPP-33. Three condition under which saturation binding 
kinetics were devised, which were binding in the presence of tubulin only, binding in the 
presence of MAPs only, and binding in the presence of tubulin + MAPs.  The concentrations of 
tubulin and MAPs were identical to that of the tubulin polymerization assay.   
Saturation kinetic data from the tubulin only system showed that there are two possible 
mechanisms for [3H]5HPP-33 binding to tubulin.  In one possible scenario, 5HPP-33 has two 
binding sites on the microtubule, which upon binding to either site on the tubulin dimer can 
cause aberrant polymer formation can occur.  The other possible mechanism is that there is 
binding only to one site on the tubulin dimer, and that the aggregation reaction just exhibits itself 
as two site binding, which is common with the vinca domain binding compounds.44 
The Hill slopes were calculated to be ~2 and ~6 for the high and low affinity Kd values 
respectively.  The Hill slope coefficient supplies information about the nature of the interaction 
between ligand and protein.73  A Hill slope deviation from unity indicates cooperativity, which 
occurs when the binding of one ligand causes a conformational change in the protein-binding site 
that leads to activation or inhibition of the binding of a second ligand molecule.  Cooperativity 
can be negative or positive, as well as homotropic or heterotropic.  If the Hill slope is > 1, this 
indicates positive cooperativity and that the binding of one ligand increases the affinity of the 
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binding of a second.  If the Hill slope is < 1, negative cooperativity is occurring and the binding 
of one ligand decreases the affinity of a second binding.  Homotropic cooperativity involves the 
same substrate and heterotropic cooperativity is between different substrates.128  The Hill slope 
for [3H]5HPP-33 binding deviated from unity, but unfortunately this does not necessarily mean 
that cooperativity is occurring.  The deviation from unity in the Hill slope is most likely due to 
the self-association of tubulin dimers in the presence of [3H]5HPP-33 as witnessed in the 
electron microscropy analyses.125  This association does not have to occur with conformational 
change to the binding site.   
The Kd values determined in both systems are not true determinations of the values, but 
probably represent a mixture of the relative Kd values for each individual step in the aggregation 
reactions.  Further studies involving ultracentrifugation reactions to determine sedimentation 
coefficients and extent of aggregation are needed to determine reaction rates, and the type of 
self-association occuring.129, 130   
The binding of [3H]5HPP-33 to MAPs was observed at concentrations above 50 μM, and 
the binding occurred in a concentration dependent manner.  Unfortunately, a Kd value could not 
be determined for this interaction because of solubility issues.    
The saturation binding graph generated from the tubulin + MAPs system was different 
from the plot obtained in the tubulin only system.  This graph showed only one binding site for 
[3H]5HPP-33, and the transformation of the this data into a scatchard plot showed only one 
downward curve.   
It is now plausible to say from the combined data from all three systems that 5HPP-33 
probably does not bind to two sites on the tubulin heterodimer, but the aggregation reaction 
disguises itself as two binding sites.  The binding to the second site was not observed in the 
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tubulin + MAPs at the concentrations used in the tubulin only system.  From the tubulin 
polymerization assays it is known that the aggregation reaction caused by 5HPP-33 is lessened in 
the presence of MAPs.  This is due to the competition between MAPs and tubulin for 5HPP-33.   
The small molecule estramustine is known to compete with paclitaxel in a non-
competitive manner for its binding site, and binds to two sites on the tubulin dimer.131  It has also 
been reported that estramustine has an affinity for binding to MAPs.132, 133  
Cemadotin, a synthetic analogue of dolastatin 15, shares many common characteristics 
with 5HPP-33.  Cemadotin does not inhibit the binding of any know microtubule agents, appears 
to have two binding sites on tubulin, and has an IC50 value for the inhibition of tubulin assembly 
20 times lower than its Kd.   
In conclusion, 5HPP-33 is a small, easily synthesized, potential chemotherapeutic agent, 
which blocks cells in the G2/M phase and exerts it activity by perturbing microtubule dynamics.  
The kinetics of binding of this agent were characterized, and it seems to have a novel mechanism 
through which it inhibits microtubule polymerization. Further analysis of this compound might 
lead to a useful new set of microtubule perturbing agents.   
 
 98 
5.0  EVALUATION OF POTENTIAL MICROTUBULE INHIBITORS 
5.1   THE MICROTUBULE DESTABILIZER (–)-PIRONETIN 
(–)-Pironetin is a small natural product that contains an ?,?-unsaturated lactone, six stereocenters 
and an alkyl chain.  Originally described as a potent inhibitor of plant growth, it was isolated 
from the bacterial broth of Streptomyces sp. NK10958.134  It was later recognized that (–)-
pironetin arrests cancer cells in G2/M phase and is a potent inhibitor of microtubule assembly. It 
is also retains its activity against multi-drug resistant cell lines.  It has been suggested that (–)-
pironetin forms a covalent bond to Lys352 on ?-tubulin, which is found near the interface of the 
heterodimers.135 This places (–)-pironetin in proximity to the nucleotide exchangeable site on ?-
tubulin, the site at which the vinca alkaloids bind.44 
Recently, Shen et al. reported on the total synthesis of (–)-pironetin using their novel 
alkaloid catalyzed acyl halide (ACC) methodology.136  Using this methodology, four compounds 
were synthesized, (–)-pironetin in two-steps with a 56% yield, the optical antipode (+)-pironetin, 
3-hydroxypironetin, and pironetin-2,4-dione.  The structures of these compounds are shown in 
Figure 33.  
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The short and efficient synthesis of (–)-pironetin and its reported potent cytotoxic and 
microtubule inhibitory properties make it a possible drug candidate.  In order to learn more about 
the mechanism of action of (–)-pironetin, cellular and biochemical evaluation of it and its 
analogues was performed.   
5.1.1 Cellular effects of (–)-pironetin and its analogues as determined by multiparameter 
immunoflourescence microscopy 
This work was performed in Dr. Andreas Vogt’s lab in the Department of Pharmacology, School 
of Medicine, at the University of Pittsburgh. To assess the mitotic effects of (–)-pironetin and its 
analogues on cells, HeLa cells were treated with indicated concentrations of compounds, the 
nucleus stained with Hoechst 33342, and incubated with primary antibodies against ?-tubulin 
and phosphorylated histone H3. Fluorescently-labeled secondary antibodies were then added that 
are conjugated to Cy3 and FITC.  Minimum detectable effective concentration (MDEC) values 
are presented in Table 12.  The MDEC values were calculated for nuclear condensation, 
microtubule mass, and histone H3 phosphorylation.  
 
Figure 33.  (–)-Pironetin and its analogues 
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Table 12.  Effects of (–)-pironetin and its analogues on HeLa cells determined using 
immunofluorescence microscopy  
 
The values reported are the average + S.D. of three independent experiments.  The 
proportion of cells undergoing mitosis, the mitotic index, was calculated using the percentage of 
cells positive for phosphorylated histone H3.  The optical antipode of pironetin and pironetin-
2,4-dione were inactive in this assay.  MDEC values for (–)-Pironetin were comparable to the 
values for vincristine and paclitaxel.  (–)-Pironetin caused increased chromatin condensation and 
phosphohistone H3 levels.  3-Hydroxy-2,3-dihydropironetin was not as active as (–)-pironetin, 
but possessed MDEC values < 1 μM.    
Fluorescent microscopy images of HeLa cells were obtained after treatment with 
equipotent concentrations of (–)-pironetin, its analogues, and vincristine. These are presented in 
Figure 34.   
 
 
 
 
 
 
 
Compound 
Nuclear 
Condensation 
 
Mitotic Index 
 
Microtubule Mass 
 MDEC (nM) 
(–)-Pironetin 7.0 ± 1.5 6.2 ± 1.0 7.1 ± 1.6 
(+)-Pironetin > 5000 > 5000 > 5000 
Pironetin-2,4-dione > 10000 > 10000 > 10000 
3-Hydroxy-2,3-dihydro-
pironetin 
242 ± 16 278 ± 46 276 ± 25 
Vincristine 2.5 ± 2.0 1.9 ± 1.3 2.5 ± 1.3 
Paclitaxel 5.3 ± 5.3 2.82 ± 1.5 4.3 ± 2.7 
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Upon treatment with the compounds, there was loss of the normal microtubule network within 
the cell and the formation of tubulin aggregates. The effects of (–)-pironetin, the 3-hydroxy-
analogue, and vincristine on microtubules appear to be very similiar.  It is known that vincristine 
is a potent inhibitor of microtubule polymerization, and it can be extrapolated from the images 
that (–)-pironetin and its analogue work by the same mechanism.  
 
 
DMSO Vincristine 
(–)-Pironetin 3-Hydroxy-2,3-dihydropironetin 
Figure 34.  Immunofluorescence images of HeLa cells 
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5.1.2 Antiproliferative effects of (–)-pironetin and its analogues  
This work was performed in Dr. Andreas Vogt’s lab in the Department of Pharmacology and 
Chemical Bioligy, School of Medicine, at the University of Pittsburgh. Breast, lung and 
glioblastoma cells were treated with (–)-pironetin and its analogues for 72 h to determine the 
antiproliferative activities of the compounds.  DC-3F Chinese hamster cell lines rendered 
resistant to multiple drugs by overexpression of the P-glycoprotein pump were used to assess if 
(–)-pironetin and its analogues would retain activity in cells containing the ABCB1 transporter.  
The GI50 values were determined as described in Chapter2.  Briefly, cells were exposed to MTS 
and cell number was determined spectrophotometrically at 490 nm minus exposure at 630 nm.  
The GI50 values for (–)-pironetin and its analogues were calculated as an average + S.D. of three 
independent experiments.  The fold resistance was calculated from dividing the GI50 value in the 
VCRd5L line by the GI50 value in the DC-3F Chinese hamster cell line.  (–)-Pironetin gave GI50 
values in the low nanomolar range for all cell lines tested and maintained activity against the 
multidrug resistant Chinese hamster cells. 
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Table 12.  Antiproliferative ability of (–)-pironetin and its analogues in various cancer cell lines 
Compound GI50 + S.D. 
90 
  MCF-7 T98G A549 MDA-
MB231 
DC-3F VCRd5L Fold 
resistance 
(–)-Pironetin 5.0 ± 0.2 7.5 ± 1.2 7.5 ± 0.9 4.6 ± 1.2 9.5 + 1.2 31 ± 5 3.2 
(+)-Pironetin 47000 ± 
3000 
30000 ± 
3000 
> 5000 > 5000 ND     
Pironetin-2,4-
dione 
> 50000 > 50000 > 10000 > 10000 ND ND   
3-Hydroxy-2,3-
dihydropironetin 
370 ± 40 740± 160 179 ± 22 168 ± 65 338 ± 66 1118 ± 56 3.3 
Vinblastine 3.5 ± 0.1 < 0.8           
Vincristine ND ND 10.8± 
2.9 
5.5 ± 3.1 19 ± 16 >> 5000 >> 250 
Paclitaxel 10.9± 0.2 24.0 ± 9.0 3.5 ± 0.5 1.6 ± 0.9 45 ± 11 2682 ± 
109 
59 
 
Vincristine and paclitaxel gave low nanomolar GI50 values in all cell lines tested except 
for the multidrug resistant Chinese hamster cell line.  There was a greater than 250- and 59-fold 
increase in the GI50 values for vincristine and paclitaxel, respectively.  From this information, it 
seems possible that (–)-pironetin and the vincas differ in the mechanisms through which they 
interact with cells.  
5.1.3 Effects of (–)-pironetin and its analogues on tubulin assembly 
To test the hypothesis that (–)-pironetin is mechanistically distinct from the vinca alkaloids in its 
ability to inhibit tubulin assembly, tubulin polymerization assays were performed as described in 
Chapter 2.  Dr. Raghavan Balachandran performed this work in the Day lab.  The MSG system 
was used to induce polymerization as described in Chapter 2.  Briefly, compounds were 
incubated with 0.8 M MSG pH 6.6, 4% DMSO and 1.0 mg/mL tubulin for 15 min at 30 oC. The 
reaction mixture was cooled to 0 oC, GTP was added to the cuvettes for a final concentration of 
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400 μM, and tubulin polymerization was followed spectrophotometrically at 350 nm.  The 
results of the experiment are presented in Figure 35.   
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Panel A in Figure 35 shows tubulin assembly in the presence of indicated concentrations of 
vinblastine.  At a concentration of 5 μM, vinblastine completely inhibited tubulin assembly.   
Panel B presents the tubulin assembly in the presence of 40 μM (–)-pironetin, which caused the 
appearance of a sigmoidal curve. The aggregation, which was visualized in the 
immunofluorescence images of cells, probably corresponds to the increase in polymerization 
seen in this assay.  (–)-Pironetin delayed the onset of assembly, but the aggregation continued 
until it reached a steady state.  The polymer former was stable to cold disassembly.  From this 
assay, it appears that (–)-pironetin is mechanistically different from vinblastine in its ability to 
Figure 35.  Tubulin polymerization assays comparing concentration dependent assembly in the presence  
of vinblastine and (–)-pironetin 
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inhibit tubulin polymerization, and may be distinct from any microtubule inhibitor previously 
characterized. 
5.1.4 Inhibition of [3H]vinblastine by (–)-pironetin and its analogues  
 A competitive inhibition binding assay was performed to assess the ability of these compounds 
to compete with [3H]vinblastine for its binding site on the tubulin heterodimer.  This assay also 
provided further evidence that (–)-pironetin is mechanistically distinct from the vinca alkaloids.  
This result was very different from anything obtained with previous microtubule inhibitors.  The 
results of the inhibition assay are shown in Table 13. 
 
Table 13.  Competitive inhibition assay utilizing [3H]vinblastine 
Test Agent % Inhibition of [3H]Vinblastine 
Vincristine 65 + 2 
Vincristine (50 μM) 98 + 1 
Dolastatin 10 61 + 1 
(–)-Pironetin 15 + 4 
(+)-Pironetin 3 + 7 
Pironetin-2,4-dione 3 + 8 
3-Hydroxypironetin 6 + 7 
Colchicine –11 + 12 
 
The percent inhibition values are reported as the average + S.D. of two experiments with each 
sample processed in duplicate.  Vincristine and dolastatin 10 are well known inhibitors of 
[3H]vinblastine binding, demonstrating their function as positive controls.44  As shown in Table 
13, 5 μM vincristine and dolastatin 10 inhibited the binding of 10 μM [3H]vinblastine to tubulin 
by 65 + 2 and 61 + 1%  respectively.  (–)-Pironetin inhibited the binding of [3H]vinblastine by 15 
+ 4%.  Neither the analogues of pironetin nor the antipode showed any appreciable inhibition 
 106 
binding.  Colchicine was used as the negative control and did not compete for [3H]vinblastine for 
its binding site.   
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5.2 THE TUBULYSINS  
 
Tubulysins are potent microtubule inhibitors isolated from the myoxbacterial strains 
Arthangium gephyra and Angiococcus discoformis.90, 137, 138 The tubulysins are metabolic 
peptides with a general sequence of D-methylpipecolate-L-isoleucine-L-tubuvaline-L-
tubuphenylalanine.  There is considerable structural similiarity between the microtubule 
destabilizers dolastatin 10 and the hemiasterlins with the tubulysins.   
 A problem that is often encountered with the use of peptides as potential drug candidates 
in vivo is low bioavailability.139  The structure of most of the tubulysins contains a labile N,O 
acetal functionality.  To improve on the stability of the tubulysins but retain biological activity, 
Wipf et al. synthesized N14-desacetoxytubulysin H (WZY-111-63C).140  In this compound, the 
N,O acetal is replaced with an N-alkyl group. Two other compounds, WZY-111-64A and WZY-
111-64A, were prepared as a means to simplify the synthesis and increase bioavailability. The 
structures are presented in Figure 36.   
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 Figure 36. Structural analogues of the tubulysins 
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Several assays were performed to assess the effect that these changes had on microtubule 
inhibitor properties and cytotoxic abilities.   
5.2.1 Antiproliferative effects of the tubulysins 
This work was performed, with my gratitude, by Dr. Raghavan Balachandran in the Day lab.  
The cytotoxic ability of the tubulysin analogues was assessed in T98 glioblastoma cells.  
Glioblastoma is the most common and aggressive type of brain tumor.141  The average GI50 
values + S.D. were determined from four independent experiments.  The cells were treated with 
the compounds and incubated for either 96 h or 72 h.   After exposure to MTS the GI50 values 
were determined spectrophotometrically.  The results of the experiment are presented in Table 
14. 
 
Table 14.  Antiproliferative effects of the tubulysin analogues. 
 
The GI50 values for N
14-desacetoxy tubulysin H (WZY-111-63C) were in the low 
nanomolar range for both time points.  The cytotoxicity of N14-desacetoxy tubulysin H (WZY-
111-63C) was comparable to the positive control vinblastine and was more active in this assay 
than paclitaxel.   The other two analogues were not as active and possessed submicromolar GI50 
values.  
Compound T98 Glioblastoma cells GI50 + S.D.  
 96 h 72 h 
N
14-desacetoxytubulysin H 
(WZY-111-63C) 
1.6 + 0.8 4.4 + 11 
WZY-111-64A 400 + 30 590 + 1000 
WZY-111-69A 350 + 40 430 + 130 
Paclitaxel 12 + 7 24 + 9 
Vinblastine 1.0 + 0.6 8.6 + 0.9 
Dolastatin 10 0.056 + 0.025 0.1 + 0.02 
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5.2.2 The effects of the tubulysins on tubulin assembly 
The tubulysins have been reported to be potent inhibitors of microtubule assembly.90  To 
determine the ability of the tubulysin analogues to inhibit microtubule assembly, assays were 
performed with purified tubulin.  A tubulin polymerization assay utilizing the MSG system was 
performed as described in the Materials and Methods section.  IC50 values were determined for 
each analogue as previously described.  An example of the tubulin polymerization graphs 
obtained for N14-desacetoxy tubulysin H (WZY-111-63C) are presented in Figure 37. 
 
 
 
 
 
 
 
 
 
 
 
The IC50 values determined from the tubulin polymerization graphs are presented in 
Table 15. N14-Desacetoxy-tubulysin H (WZY-111-63C) was the most potent inhibitor of GTP-
induced tubulin assembly and was comparable to the positive control values for the known 
inhibitors vinblastine and dolastatin 10.  WZY-111-69A was a potent compound as well with an 
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Figure 37. Effects of N14-desacetoxy tubulysin H (WZY-111-63C) on tubulin assembly 
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IC50 value of 3.1 μM.  WZY-111-64A had barely an effect on tubulin assembly and had an IC50 
> 5 μM. 
 
Table 15.  Fifty percent tubulin assembly inhibition values for the tubulysin analogues. 
Compound Tubulin Assembly Inhibition IC50 (μM) 
N
14-desacetoxytubulysin H (WZY-111-63C) 2.3 
WZY-111-64A >5 
WZY-111-69A 3.1 
Vinblastine 1.6 
Dolastatin 10 1.4 
 
5.2.3 Ability of tubulysin analogues to compete with radiolabeled vinca domain binding 
agents 
The ability of the tubulysin analogues to compete with potent vinca domain binding agents was 
tested. For the most potent compounds, IC50 values were determined by fitting the data to the 
Hill equation. The percent inhibition values for the assays utilizing [3H]vinblastine and 
[3H]dolastatin 10 are presented in Table 16.  The percent inhibition and IC50 values are the 
average + S.D. of two experiments with each sample processed in duplicate.   
 
Table 16. Percent Inhibition and IC50 values for the vinca domain binding assays. 
 
Compound 
Inhibition of [3H]Vinblastine 
binding and test agent IC50 
Inhibition of [3H]Dolastatin 10 
binding and test agent IC50 
N
14-desacetoxytubulin H 50 + 4% (5.6 + 0.5 μM) 31 + 3% (10 + 1 μM) 
WZY-111-64A 2 + 5% (>50 μM) –11 + 10% (ND) 
WZY-111-69A 43 + 1% (8.8 + 1.6 μM) 4 + 3 (64 + 9 μM) 
Dolastatin 10 61 + 1% (4.6 + 0.5 μM) N/A 
Vincristine 65 + 2% (4.4 + 0.7 μM) 21 + 5% (29 + 5 μM) 
Colchicine –11 + 12% –5 + 8% 
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Colchicine was used a negative control and vincristine as a positive control in both assays.  
Dolastatin 10 was used as a second positive control in the [3H]vinblastine binding assay. The 
ability of the analogues to inhibit the binding of [3H]vinblastine and [3H]dolastatin 10 into 
microtubules was in the order N14-desacetoxytubulysin H (WZY-111-63C)>WZY-111-
69A>>WZY-111-64A.   
The analysis of the binding data for the determination of the IC50 for the [
3H]vinblastine 
assay and [3H]dolastatin 10 is presented in Figure 38.  The Hill slopes were >1 for all binding 
sets. The concentration-dependent inhibition binding curves for the [3H]vinblastine assay are 
shown in Panel A of Figure 38.  Vincristine had the lowest IC50 at 4.4 + 0.7 μM, but the IC50 for 
N
14-desacetoxytubulysin H (WZY-111-63C) was comparable, 5.6 + 0.5 μM.  The IC50 for WZY-
111-69A was 8.8 + 1.6 μM. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 38.  Concentration-dependent inhibition of binding of radiolabeled ligands to bovine brain tubulin 
A B 
log10 Concentration (μM) log10 Concentration (μM) 
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The concentration-dependent inhibition curvers for the [3H]dolastatin 10 binding assay are 
shown in Figure 38 Panel B.  Vincristine was used as the positive control and the calculated IC50 
was 29 + 5 μM.   IC50 values calculated for N14-desacetoxytubulysin H (WZY-111-63C) and 
WZY-111-69A were 10 + 1 and 64 + 9 μM, respectively. 
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5.3 DISCUSSION 
(–)-Pironetin is a small molecule microtubule inhibitor that probably acts by formation of a 
covalent bond to Lys352.138  Preparation using the AAC methodology represents a simple 
synthetic route for the production of (–)-pironetin.136  From the studies presented here, it is clear 
that (–)-pironetin is a potent inhibitor of cell proliferation, retains potency against multi-drug 
resistant cell lines, and differs in its mechanism from traditional microtubule inhibitors. 
 From the multiparameter cell based immunofluorescence assay, it was clear that (–)-
pironetin was an antimitotic agent, and from the immunofluorescence images it was ascertained 
that it caused tubulin aggregation.  This suggested that the compound acts in a mechanism much 
like the vinca domain binding agents.  However, tubulin polymerization and competitive percent 
inhibition assays with radiolabeled [3H]vinblastine, indicate that (–)-pironetin is a novel 
microtubule inhibitor.   
 The (–)-pironetin analogue, 3-hydroxy-2,3-dihydropironetin, was the only analogue 
examined that possessed any biological activity.  Although it was active in the cellular assay, it 
did not possess any ability to inhibit tubulin assembly (data not shown) or the binding of 
[3H]vinblastine.  One possible explanation for this is that 3-hydroxy-2,3-dihydropironetin is 
metabolized in vivo to an active form, perhaps pironetin.  This indicates the possible use of this 
compound as a prodrug.   
 The sigmoidal shape of the graphs obtained in the tubulin polymerization graphs is 
probably due to the aggregation reaction formed in the presence of (–)-pironetin.  The delay in 
the onset of assembly is maybe due to the formation of the covalent linkage, which then causes 
the aggregation reaction.    
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  (–)-Pironetin is a weak inhibitor of [3H]vinblastine binding.  The results presented here for 
the [3H]vinblastine binding assay coincide with those previously reported by Kondoh et al., 
although their results suggest a higher percentage of inhibition.142  This may be due to the 
differences in the amount of protein, tracer and inhibitor that were used in the two experiments.  
In the inhibition assay used here, the ratio of tubulin, tracer and inhibitor was 1:1:0.5.  The 
experiment was performed in this ratio because it provided a quick and easy method of 
comparing the positive controls to the test compounds.  This is in comparison to Kondoh’s assay, 
which was performed in the ratio of 1:0.01:10.  The 20-fold greater concentration of inhibitor 
used in Kondoh’s assay may account for the discrepancy in the percent inhibition values between 
the two experiments.   
The formation of a covalent bond to Lys352, near the interface of the dimers, places (–)-
pironetin in proximity to the nucleotide exchangeable site on ? tubulin. The results from the 
[3H]vinblastine competitive binding assay were in agreement with the proposed mechanism of 
binding for (–)-pironetin. The covalent linkage of  (–)-pironetin to Lys352 should prevent 
[3H]vinblastine from binding to its site on ? tubulin near the exchangeable nucleotide site at the 
tubulin heterodimer interface.  Usui et al. have already proposed that this explains the weak 
inhibition of [3H]vinblastine binding by (–)-pironetin.135 
The formation of a covalent linkage might be a way of overcoming P-glycoprotein 
resistance resistance. The formation of a covalent bond between tubulin and compound 
neutralizes this resistance mechanism because the compound may no longer be actively pumped 
out of the cell.49  This mechanism has been reported for the microtubule stabilizer 
cyclostreptin.31  Cyclostreptin forms a covalent linkage to Thr 220 and Asn 228 within the 
paclitaxel binding site on ?-tubulin.  Unlike paclitaxel, cyclostreptin retains its activity in multi-
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drug resistant cell lines, suggesting that a covalent linkage overcomes this resistance.75  The 
same mechanism maybe true involving microtubule inhibitors and could represent a future 
strategy for combating resistance during chemotherapy.  Although covalent modifiers are usually 
not favorable drug candidates, there are examples in clinical use.143, 144  An example that is used 
clinically as a chemotherapeutic agent, is the covalent modification of DNA by platinum agents.   
Since the isolation and characterization of the tubulysins from myxobacteria, there has 
been a considerable amount of progress made towards the synthesis of the isolated tubulysins 
and synthetic analogues.140, 145-147  This has been due in large part to the discovery that tubulysin 
A is a powerful cytotoxic agents, a potent microtubule inhibitor, and that there is limited supply 
from available sources.  The limited supply makes it necessary to find synthetic routes, and the 
pharmacophore through modifications to the tubulysin scallfold.   
To make a suitable drug candidate a compound must be bioactive, stable, and 
bioavailable.139  Towards this goal, identifying potential labile or reactive groups is important 
when preparing a molecule to become a drug candidate. Changing these sites often increase 
bioavailabilty and the half-life of the compound in vivo.148   
Three analogues were synthesized that removed a labile N,O-acetal functionality in the 
tubulysin scaffold.  The change in this reactive group would hopefully serve to increase 
bioavailbilty without a loss in activity.  N14-desacetoxy-tubulysin H (WZY-111-63C) contained 
only one modification, which was the replacement of the N,O-acetal function with an N-alkyl 
group.  The WZY-111-69A analogue removed the N-methylpipecolate residue and replaced it 
with an N,N-dialkylated amino acid.  The third analogue, WZY-111-64A, contained all of the 
previously mentioned modifications and an epimerized stereocenter at C11.   
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The ability of the tubulysin analogues to inhibit the polymerization of tubulin into 
microtubules was in the order WZY-111-63C>WZY-111-69A>>WZY-111-64A.  The ability of 
the compounds to inhibit the binding of [3H]vinblastine and [3H]dolastatin 10 mirrored the 
tubulin polymerization data.  From this data, three conclusions were reached:  the N,O acetal at 
N14 is not necessary for activity; replacement of the D-methylpipecolate residue with the simpler 
N-methylsarcosine reduces the affinity of the compound for the vinca domain binding site but 
still retains nanomolar potency in cancer cells; and the C11 natural configuration is required for 
biological activity.  This data provided further insight the structure activity relationships for the 
tubulysins and also supplied important information that may improve the efficacy of tubulysin in 
vivo.   
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6.0  FUTURE DIRECTIONS 
The discovery that 6-epi-dictyostatin is a potent analogue of (–)-dictystatin prompted the 
milligram synthesis of this compound for use in preclinical trials.  It has already been tested in 
mice bearing MDA-MB231 xenografts (Eiseman et al., unpublished results).  6-epi-Dictyostatin 
was administered intravenously at a concentration of 20 mg/kg to mice three times every 7th day.  
Around 14 days mice treated with vehicle or control had to be euthanized due to tumor burden, 
but mice treated with 6-epi-dictyostatin did not have a substantial increase in tumor mass even 
after 34 days.  Paclitaxel at the same concentration and dosing schedule was used as a positive 
control in this experiment.  Animals dosed with paclitaxel had to be euthanized after 24 days due 
to tumor burden.  They were some loss in body weight of animals treated with 6-epi-dictyostatin 
but it was less than 10%.  
This first animal study proved that 6-epi-dictytostatin is a viable possibility for a future 
chemotherapeutic agent.  Further studies in mice bearing other xenografts will assess the efficacy 
of this drug against multi-drug resistant and other types of tumors.  Specimens of body fluids 
were taken from the animals after dosing to determine the metabolites of 6-epi-dictyostatin 
formed in vivo, and pharmacodynamic and pharmacokinetic parameters will be established in the 
mouse model for 6-epi-dictyostatin.   
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 Combination chemotherapy may become the most effective way to treat cancer.  Huang 
et al. have already proven the efficacy of combination of discodermolide and paclitaxel treatment 
in mice bearing human ovarian cancer cell xenografts.149  The synergistic effects of peloruside A 
and laulimalide with other microtubule perturbing agents has already been evaluated.150  Due to 
the novel properties of 5HPP-33, it can be hypothesized that a synergistic interaction might exist 
between it and other microtubule perturbing agents.  Chou and Talalay reported the traditional 
method of reporting synergism, and this will be used to determine the antiproliferative effects of 
a combination treatment in a variety of cell lines.151 
 It has been established that (–)-pironetin binds to tubulin in a covalent manner through an 
interaction with Lys352 on ?-tubulin.135 The toxicity aspects of this compound must be 
determined before use in a clinical setting.  Preclinical studies with mice will be performed to 
determine the efficacy and toxicity of (–)-pironetin.   
The (–)-pironetin analogue 3-hydroxy-2,3-dihydropironetin was active in cellular assays 
but not in assays involving isolated tubulin. A time dependent cellular study must be performed 
to identify the active species of this compound.    
 Currently, more tubulysin analogues are being made to increase bioavailability and to 
reduce synthetic difficulty.  These analogues will be tested to determine their antiproliferative 
effects and microtubule perturbing abilities.  From this study, a compound might be chosen for 
scaled-up synthesis so as to take it into preclinical studies.   
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APPENDIX A 
 
 
Spectral and HPLC data for key intermediates and the radiolabeled compound. 
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